A REVIEW OF EVIDENCE OF ADVERSE HEALTH EFFECTS
ASSOCIATED WITH BLOOD LEAD LEVELS <10 µg/dL IN CHILDREN

Reported by

Work Group of the Advisory Committee on
Childhood Lead Poisoning Prevention

to

CENTERS FOR DISEASE CONTROL AND PREVENTION
National Center for Environmental Health

October 7, 2004
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMMARY</td>
<td>iv</td>
</tr>
<tr>
<td>WORK GROUP MEMBERS</td>
<td>vi</td>
</tr>
<tr>
<td>ABBREVIATIONS AND ACRONYMONS</td>
<td>vii</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>1</td>
</tr>
<tr>
<td>REVIEW METHODS</td>
<td>3</td>
</tr>
<tr>
<td>RESULTS</td>
<td>8</td>
</tr>
<tr>
<td>Studies Relating Postnatal Lead Exposure to IQ or General Cognitive Index</td>
<td>8</td>
</tr>
<tr>
<td>Studies of Health Endpoints Other than IQ and CGI</td>
<td>9</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>12</td>
</tr>
<tr>
<td>Biologic Plausibility</td>
<td>12</td>
</tr>
<tr>
<td>Blood Lead Measurement</td>
<td>15</td>
</tr>
<tr>
<td>Blood Lead Age Trend, Tracking, and Inference Concerning Blood Lead - Effect Relations in Children</td>
<td>17</td>
</tr>
<tr>
<td>Quality of Neurobehavioral Assessments</td>
<td>19</td>
</tr>
<tr>
<td>Potential Confounding Factors</td>
<td>21</td>
</tr>
<tr>
<td>Causal Direction</td>
<td>25</td>
</tr>
<tr>
<td>OVERALL CONCLUSIONS</td>
<td>27</td>
</tr>
<tr>
<td>RESEARCH NEEDS</td>
<td>29</td>
</tr>
<tr>
<td>APPENDIX A: LITERATURE REVIEW AND CLASSIFICATION UPDATE</td>
<td>A-1</td>
</tr>
<tr>
<td>APPENDIX B: CRITIQUE OF NHANES III DATA BY STONE, ET AL. (2003)</td>
<td>B-1</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>R-1</td>
</tr>
</tbody>
</table>

## List of Figures

- **Figure 1.** Expected variation in regression slopes given hypothetical “true” threshold blood lead - IQ relation (A). .................................................................................. 30
- **Figure 2.** Cognitive Function Regression Coefficients for Blood Lead Age ≤ 2 years and Outcome Age ≥ 4 years. ........................................................................................................ 32
- **Figure 3.** Cognitive Function Regression Coefficients for Blood Lead Age ≥ 4 years and Outcome Age ≥ 4 years. ........................................................................................................ 33
- **Figure 4.** Age trend in blood lead levels. ................................................. 34
- **Figure 5.** Hypothetical observed blood lead – IQ association. .................. 35
- **Figure 6.** Hypothetical “true” blood lead –IQ relationship. ....................... 35
- **Figure 7.** Hypothetical blood lead IQ slopes associated with residual confounding (see text). .............................. 36

October 7, 2004
A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

List of Tables

| Table 1. | Lowest blood lead level (BLL) considered elevated by CDC and the US Public Health Service | 37 |
| Table 2. | Summary of studies estimating association of postnatal PbB with cognitive function | 38 |
| Table 3. | Summary of studies estimating association of postnatal PbB with performance scale IQ | 53 |
| Table 4. | Summary of studies estimating association of postnatal PbB with verbal scale IQ | 59 |
| Table 5. | Studies of health endpoints other than IQ or GCI in relation to BLLs <10 µg/dL | 65 |
| Table 6. | Selected methodologic details from cohort studies | 70 |
Executive Summary

Page intentionally left blank.
Page intentionally left blank.
A Review of Evidence of Adverse Health Effects Associated with Blood Lead Levels <10 µg/dL in Children

Reported by
A Work Group of the CDC Advisory Committee on Childhood Lead Poisoning Prevention on Health Effects of Blood Lead Levels <10 µg/dL in Children

Work Group Members

Michael Weitzman, MD
Work Group Chair
Center for Child Health Research
University of Rochester

Patrick J. Parsons, PhD
Wadsworth Center for Laboratories and Research
New York State Department of Health

Joel Schwartz, PhD
Department of Environmental Health
Harvard School of Public Health

Betsy Lozoff, MD
Center for Human Growth and Development
University of Michigan

David Bellinger, PhD
Neuroepidemiology Unit
Children's Hospital
Harvard Medical School

Kimberly M. Thompson, ScD
Department of Health Policy and Management
Harvard School of Public Health

David A. Savitz, PhD
Department of Epidemiology
University of North Carolina School of Public Health

Birt Harvey, MD
Pediatrician
Palo Alto, California

Carla Campbell, MD
Division of General Pediatrics
The Children’s Hospital of Philadelphia

This review was prepared for the work group by the following:

Thomas D. Matte, MD, MPH
David Homa, PhD
National Center for Environmental Health
Centers for Disease Control and Prevention

and

Jessica Sanford, PhD
Alan Pate
Battelle Memorial Institute
# Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAS</td>
<td>atomic absorption spectrometry</td>
</tr>
<tr>
<td>ACCLPP</td>
<td>Advisory Committee on Childhood Lead Poisoning Prevention</td>
</tr>
<tr>
<td>ALAD</td>
<td>amino levulinic acid dehydratase</td>
</tr>
<tr>
<td>ASV</td>
<td>anodic stripping voltammetry</td>
</tr>
<tr>
<td>ATSDR</td>
<td>Agency for Toxic Substances and Disease Registry</td>
</tr>
<tr>
<td>BLL</td>
<td>blood lead level</td>
</tr>
<tr>
<td>EBLL</td>
<td>elevated blood lead level</td>
</tr>
<tr>
<td>EP</td>
<td>erythrocyte protoporphyrin</td>
</tr>
<tr>
<td>EPA</td>
<td>Environmental Protection Agency</td>
</tr>
<tr>
<td>ETAAS</td>
<td>electrothermal atomization techniques based on the graphite Furnace</td>
</tr>
<tr>
<td>ETS</td>
<td>environmental tobacco smoke</td>
</tr>
<tr>
<td>FEP</td>
<td>free erythrocyte protoporphyrin</td>
</tr>
<tr>
<td>GCI</td>
<td>General Cognitive Index</td>
</tr>
<tr>
<td>GFAAS</td>
<td>graphite furnace atomic absorption spectrophotometry</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>HOME</td>
<td>Home Observation for Measurement Environment</td>
</tr>
<tr>
<td>ICP-MS</td>
<td>inductively coupled plasma mass spectrometry</td>
</tr>
<tr>
<td>ID-MS</td>
<td>isotope dilution mass spectrometry</td>
</tr>
<tr>
<td>MCV</td>
<td>mean corpuscular volume</td>
</tr>
<tr>
<td>MDI</td>
<td>Mental Developmental Index of the Bayley Scales of Infant Development for children</td>
</tr>
<tr>
<td>MSCA</td>
<td>McCarthy Scales of Children’s Ability</td>
</tr>
<tr>
<td>NCCLS</td>
<td>National Committee for Clinical Laboratory Standards</td>
</tr>
<tr>
<td>NCEH</td>
<td>National Center for Environmental Health</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl-D-aspartate</td>
</tr>
<tr>
<td>PbB</td>
<td>Blood lead</td>
</tr>
<tr>
<td>PCAACN</td>
<td>Practice Committee of the American Academy of Clinical Neuropsychology</td>
</tr>
<tr>
<td>PKC</td>
<td>protein kinase C, a calcium dependent enzyme</td>
</tr>
<tr>
<td>SES</td>
<td>socioeconomic status</td>
</tr>
<tr>
<td>U-RBP</td>
<td>urinary retinal binding protein</td>
</tr>
</tbody>
</table>
WG  work group

WISC-R  Wechsler Intelligence Scale for Children – Revised

WISC-III  Wechsler Intelligence Scale for Children – Third Edition

WRAT  Wide Ranging Achievement test arithmetic and reading scores

ZPP  zinc protoporphyrin
Background

Charge to the Work Group

In March 2002, the Advisory Committee on Childhood Lead Poisoning Prevention agreed to establish a work group (WG) to review evidence of possible health effects of lead at blood lead levels less than 10 micrograms per deciliter (µg/dL), currently the threshold for defining an elevated blood lead level according to CDC guidelines (CDC 1991). The work group was charged as follows:

“In October 1991, the Centers for Disease Control and Prevention issued Preventing Lead Poisoning in Young Children. This document heralded a change in the definition of the level for intervention for children with elevated blood lead levels (EBLLs) from a lead level of 25 µg/dL to 10 µg/dL. The report explained that this change was due to new data that indicated significant adverse effects of lead exposure in children at levels once thought to be unassociated with adverse effects. The 1991 document identified a goal to reduce children’s blood lead levels below 10 µg/dL. Interventions for individual children were recommended at levels of 15 µg/dL and above.

Research findings published and disseminated since October 1991 suggest that adverse effects from lead exposure and toxicity occur at blood lead levels below 10 µg/dL. Some studies suggest that some effects may be greater at blood lead levels (BLLs) below 10 µg/dL than at higher BLLs. Such research findings raise concerns about the inability to control lead exposure with conventional methods and lend credence to the importance of primary prevention measures to prevent lead exposure to children.

The work group will be convened by the Advisory Committee on Childhood Lead Poisoning Prevention to review the existing evidence for adverse effects of lead exposure and toxicity on children at very low blood lead levels and to focus on effects at levels of 10 µg/dL and below. Rigorous criteria will be established for the literature review. The work group will then create, in conjunction with the committee, a summary of the evidence for publication.”

Scientific and Public Health Context for the WG Review

Prior reviews that compiled the extensive evidence from in vitro, animal, and human studies established lead as a multi-organ toxicant, including studies showing health effects at BLLs near 10 µg/dL (ATSDR 1999; WHO 1995; USEPA 1986). The published studies include a large body of literature establishing that lead is a developmental toxicant and that harmful effects of lead on children’s development can occur without clinical signs, symptoms, or abnormal routine laboratory tests. In addition, a growing number of studies suggest that BLLs
A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

prevalent in the general population are associated with adverse health effects in adults and in the offspring of pregnant women. Finally, in more recent years, bone-lead levels measured by x-ray fluorescence have been used in epidemiologic studies as a measure of cumulative lead exposure. Although these were not considered in this review, a number of studies showing inverse relations of bone-lead level to health in general population samples (e.g., Cheng et al. 2001) add further evidence that cumulative lead exposure may be harmful to health at typical background exposure levels for the population in the United States.

The observation that available epidemiologic evidence does not demonstrate a threshold below which no effect of lead is possible is not a new idea. A review prepared for a 1986 workshop on lead exposure and child development stated, “There is little evidence for a threshold or no-effect level below which the lead/IQ association is not found. IQ deficits have been reported in studies where the mean lead level is 13 µg/dl (Yule et al. 1981) and similar deficits in the Danish study where the primary measure was tooth lead, but BLLs are lower at around 7 µg/dL.” (Smith 1989) A review, meta-regression, and reanalysis of existing data (Schwartz 1994) reached essentially the same conclusion. Available data did not suggest a threshold below which no association between BLLs and intelligence in young children was evident. Recent studies (Canfield et al. 2003; Lanphear et al. 2000; Moss et al. 1999; Wu et al. 2003) provided more direct evidence of an association between BLLs and adverse health effects in the domains of cognitive function, neurologic function, growth, dental caries, and onset of puberty at levels well below 10 µg/dL. Thus, a reexamination of this issue is in order.

As evidence from experimental animal studies and human epidemiologic studies has grown, CDC has lowered the BLL considered elevated for the purpose of interpreting clinical test results of an individual child (Table 1). CDC guidelines also have provided criteria for identifying children who have more severe manifestations of lead toxicity and/or a higher risk of lead-related sequelae. For example, CDC’s 1975 and 1978 guidelines defined clinical “lead poisoning” on the basis of BLLs, symptoms, and/or levels of erythrocyte protoporphyrin (EP) or other indicators of lead-related biochemical derangements. CDC’s 1985 guidelines used the terms “lead toxicity” and “lead poisoning” interchangeably to refer to BLLs $25 : g/dL with EP $35 : g/dL. However, the guidelines acknowledged that “lead poisoning” is generally understood for clinical purposes to refer to episodic, acute, symptomatic illness from lead toxicity. CDC’s 1985 guidance also cautioned that blood lead thresholds established to guide follow-up and treatment for individual children “should not be interpreted as implying that a safe level of blood lead has been established.” In 1991, CDC guidelines more directly acknowledged the difficulty in assigning terms to specific ranges of BLLs given the different settings in which BLLs are interpreted and given that manifestations of lead toxicity occur along a continuum: “It is not possible to select a single number to define lead poisoning for the various purposes of all of these groups [e.g. clinicians, public health officials, and policy makers]” (CDC 1991). These guidelines also noted, “Some [epidemiologic] studies have suggested harmful effects at even lower levels [than a BLL of 10 : g/dL].”

In addition to these changes in criteria used to evaluate blood lead test results for individual children, recent analyses by the U.S. Department of Housing and Urban Development (HUD 1999) and the U.S. Environmental Protection Agency (USEPA 2000) to support the
development of regulations governing lead exposure have assumed that the relation of increasing blood lead to decrements in children’s IQ extends to BLLs <10 $\mu$/dL.

As BLLs considered elevated have fallen, measures to reduce or remove lead from a number of sources, including gasoline, soldered food and beverage containers, paint, drinking water, and industrial emissions have resulted in a dramatic decline in BLLs in the United States since the mid-1970s (Pirkle et al. 1994). The Second National Health and Nutrition Examination Survey (NHANES II) conducted from 1976 to 1980 demonstrated that, among U.S. children ages 6 months through 2 years, 84% of white children and more than 99% of black children had BLLs $\leq 10$ $\mu$/dL, and the median BLLs were 14 and 19 $\mu$/dL respectively (Mahaffey et al. 1982). A decline in BLLs during the course of that survey was noted, paralleling the falling consumption of leaded gasoline (Annest et al. 1983). A continued decline in BLLs was evident in subsequent NHANES surveys (Pirkle et al. 1994; NCEH 2003) and in clinical blood-lead test data compiled by state and local health agencies (Hayes et al. 1994; CDC 2003). Nationally, it is estimated that by 1999-2000, the prevalence of BLLs $\leq 10$ $\mu$/dL among children 1 to 5 years of age had fallen to 2.2% and the median level to 2.2 $\mu$/dL (NCEH 2003).

Although these reductions in lead exposure represent great progress, scientific advances have shed light on harmful effects of lead at levels of exposure once thought safe. In addition, industrial activity has widely dispersed lead in the environment from naturally occurring deposits. As a result, even at the lower exposure levels that prevail today, typical body burdens of lead are likely to be much higher than those present in pre-industrial humans, which by one estimate corresponded to a BLL of 0.016 $\mu$/dL (Smith et al. 1992). Therefore, the potential for additional subclinical adverse effects of lead from currently prevailing exposures deserves careful study. Finally, although falling BLLs have benefited all demographic groups (Pirkle et al. 1994), stark demographic and geographic disparities continue to reflect the historic pattern; the risk of elevated BLLs in communities where poverty and older (i.e., that built before 1950) housing are prevalent remains several fold higher than the national average (Lanphear et al. 1998).

**Review Methods**

**Scope and Approach**

Given the charge to the work group and the scientific and public health context, the WG did not attempt a comprehensive review of all evidence relating lead exposure to health. Instead, the WG set out to answer the following questions:

1. Does available evidence support negative associations between health indicators and children’s blood lead levels measured in the range <10 $\mu$/dL?

2. Are the observed associations likely to represent a causal effect of lead on health?
To address these questions, the work group established criteria (see Methods) for published studies that would address the first question. In addition, the work group identified issues relevant to making causal inference from any observed associations. Identifying such issues is an essential step in interpreting evidence relevant to the WG charge. Human studies to assess potential health effects of environmental toxicants, such as lead, are usually observational in design (i.e., the health status of participants is related to some measure of exposure, dose, or body burden that varies on the basis of environmental factors and not experimental manipulations by the investigator). For ethical reasons, the limited number of human experimental studies that have evaluated causal relations between toxicant exposures and health usually have involved attempts to reduce exposure or body burden and assess the impact on health status. Such studies of lead-exposed children are rare, and to date none have focused on children with BLLs <10 µg/dL.

Observational studies have inherent limitations – not specific to studies of lead toxicity– with the potential to produce biased results. Biases from observational studies can obscure true causal effects of toxicant exposures or produce associations between toxicant exposures and health status when no causal relation is present. Thus, statistical associations from individual observational studies or multiple studies subject to similar biases cannot establish causal relationships; additional, non-statistical criteria may be used to evaluate such evidence. Although causal criteria have been stated in various ways, the Surgeon General’s Report on Smoking and Health (U.S. Public Health Service 1964) provides a useful set of criteria. They include:

- **The consistency of the association.** Is a similar association observed across studies with varying methods and populations?

- **The strength of the association.** The strength of an association is the extent to which the risk of a disease or a measure of health status varies in relation to exposure and can be expressed, for example, as a relative risk or regression coefficient. It is distinguished from the statistical significance of an association that reflects both the strength of the association and the sample size. An additional criterion, specificity of the association, is closely related to strength of the association and is considered less important in the context of multifactorial health conditions.

- **The temporal relationship of associated variables.** Does the hypothesized causal exposure occur before the health outcome associated with it?

- **Coherence of the association.** Is the observed association consistent with other relevant facts including, for example, experimental animal studies and the descriptive epidemiology of the health condition under study?

The application of these criteria does not provide a clear demarcation for concluding definitive proof of causation versus inadequate evidence. Rather, the more the available evidence meets these criteria, the greater the confidence in causal inference about an association. Consistent with these criteria, the WG identified several issues specifically relevant to inferring
causality from associations (or the lack of associations) of BLLs to health measures observed in studies of low-level lead exposure. These potential biases are not unique to studies of children with BLLs \(\leq 10\) \(\mu\)g/dL, (e.g., Smith 1989). However, the larger number of human and experimental animal studies (including primate studies) and the nature of observed health effects associated with higher BLLs have conclusively demonstrated the adverse health effects of lead. However, far fewer studies of possible health effects of BLLs \(< 10\) \(\mu\)g/dL have been conducted, and the relative importance of some sources of bias may be greater at these lower levels. Therefore, the work group considered several issues in interpreting the findings of available studies (see Discussion).

At the time of the work group’s review, a consortium of investigators from several longitudinal studies of lead exposure and cognitive function in children were conducting a reanalysis of data pooled from these studies. These studies included serial measures of blood lead level, cognitive function, and a large number of potential confounders, thus providing stronger evidence than is available from cross-sectional studies. A focus of the pooled reanalysis involved studying the shape of the association between postnatal lead exposure at low levels and measured IQ (B. Lanphear, personal communication, 2003). The WG reviewed published reports from individual cohort studies from which data were pooled, but the final results of this pooled reanalysis were not available for inclusion in the WG report.

Because of the nature of its charge, the WG did not develop policy recommendations or address questions relevant to such recommendations. Such policy decisions and questions will, if appropriate, be considered by the full ACCLPP after reviewing the findings of this report.

Criteria for Relevant Studies

The WG initially considered, then rejected, limiting its review to studies for which published results provide direct comparisons between children with varying BLLs \(< 10\) \(\mu\)g/dL. Such a review would include a relatively small number of studies. Instead, the group decided that the larger number of studies that have included IQ as an outcome could, collectively, indirectly support or refute the existence a threshold near \(10 : g/dL\) for the blood lead-IQ association. The rationale for this approach is based on that used in a review and metaregression reported by Schwartz (1994) and outlined in the following paragraphs.

Suppose that, hypothetically, a threshold exists near \(10 : g/dL\), above which mean IQ decreases linearly with increasing blood lead, with a slope=\(x\) and below which mean IQ is not associated with blood lead\(^1\) (see Figure 1 - Hypothesized “true” relation A). In studies of children who have BLLs \(< 10\) \(\mu\)g/dL, estimated slopes would be, in the absence of sampling error, equal to 0. For studies in which all children have BLLs above the threshold, the estimated slope would be, again ignoring sampling error, equal to \(x\). For studies in which some children have blood lead above and others below the threshold, estimated slopes will vary between 0 and \(x\) as shown in Figure 1. Thus, if regression coefficients estimating the IQ-blood lead slope are

\(^1\) The concept of a threshold existing for the population makes little sense toxicologically since even if individual thresholds exist, these are likely to vary. Nonetheless, the threshold concept plays a major role in regulatory toxicology, and it only becomes clear in cases like lead that such constructs can be highly problematic.
less negative (approaching 0) in populations with lower mean BLLs than in populations with higher mean levels, a threshold near 10 would be suggested. The absence of such a trend or an increase in slopes with decreasing mean blood lead level of the population studied would provide evidence against such a threshold and instead support “true” relations B and C, respectively. This ideal hypothetical case presumes that effect sizes from the studies compared are based on models that correctly specify the form of the BLL-IQ relation and that factors that might modify the relation do not vary across studies.

Because of this approach, studies that assessed the association between blood lead and measured IQ were included in this review, even if the (as was true in most cases) published results did not examine blood lead-IQ associations limited to the range of BLLs <10 : g/dL. An additional reason for considering studies that measured IQ was the relationship of IQ to other outcomes of policy and public health importance including educational success and earnings potential (Grosse et al. 2002). Because the McCarthy Scales of Children’s Ability (MSCA) General Cognitive Index (GCI) was used in a number of studies to measure cognitive function in preschool children and because GCI and IQ scores have similar distributions, studies using GCI as an outcome were also included in this review.

The following criteria were used to select relevant studies to review for this report:

1. Blood lead levels were measured using graphite furnace atomic absorption spectrophotometry (GFAAS) or anodic stripping voltametry.

2. The study was published in English.

In addition,

For studies in which IQ or GCI was a measured outcome, the study analyses included an assessment of the association between BLLs measured in children and IQ or GCI.

For studies in which IQ or GCI was not a measured outcome, the study analyses included an assessment of the association between BLLs <10 : g/dL measured in children and a health outcome. The assessment could either be formal (e.g., non-linear modeling, linear modeling restricted to populations with all or at least 95% of children having BLLs <10 : g/dL, statistical comparison of two or more sub-groups with BLLs <10 : g/dL) or informal (e.g., graphical display of results permitting visual assessment of blood lead-outcome relation in the range <10 : g/dL).

**Literature Search**

To identify potentially relevant articles, a comprehensive report published by the Agency for Toxic Substances and Disease Registry (ATSDR 1999) was reviewed first to identify cited...
A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

Articles that related to low-level lead exposure in children. The list of potentially relevant citations identified in the ATSDR report was supplemented by three computerized literature searches, using Dialog® to search Medline, Toxfile, and other bibliographic databases. Search terms (see Appendix A) were chosen to identify articles reporting on blood lead measurements and one or more domains of health related to lead exposure including neurodevelopment, cognitive function, intelligence, behavior, growth or stature, hearing, renal function, blood pressure, heme synthesis, hematopoiesis, and Vitamin D metabolism. The first search spanned articles published from 1995 through 2002 and indexed as of September 2002, the month and year that the initial search was performed. The second search was performed in April 2003 and spanned the period 2002 through the search date. A third search, spanning the years 1990 through 1996, was performed when a relevant article not cited in the ATSDR toxicological profile was identified by one of the work group members. In addition, potentially relevant articles were identified by work group members and through citations in articles identified previously. Abstracts were reviewed initially. If they were ambiguous or if they suggested the article was relevant, full articles were checked for relevance. Articles deemed relevant were abstracted for this report. Appendix A summarizes the number of possibly relevant references identified, full articles checked for relevance, and relevant articles abstracted and considered in the review.

Structured Abstracts

For each relevant study, a structured study abstraction was performed that captured the following information: the study location, sample size, age at which blood lead was measured, age at which the outcome was measured, available information about the blood lead distribution (including mean or other measure of central tendency, variance, and percent of participants with BLLs <10 g/dL), the crude and adjusted regression coefficients relating blood lead to outcome (if available), the type of model fit (linear, log linear, or other), and the covariates included in the adjusted model. If regression coefficients were not available, other measures of association reported (e.g., correlation coefficients) were noted. Because some studies fit multiple blood lead-outcome models (e.g., cohort studies with blood lead and IQ measured at multiple ages), relevant information about each model estimated was abstracted. For IQ studies, covariates measured and not included in adjusted models were recorded when available.

Review of Cohort Study Methods

Among relevant published results were those from cohort studies specifically designed and conducted to study the relation of BLLs to children’s cognitive function and other health outcomes. Because these studies had the strongest and best-documented study designs for this review, methods used for blood lead measurement and neuropsychological assessment were summarized for these studies. This information was collected from published studies; in some cases, the studies were supplemented by information provided through correspondence with the investigators.
Results

Studies Relating Postnatal Lead Exposure to IQ or General Cognitive Index

Studies in which IQ or GCI were measured as an outcome and other criteria were met included 23 published reports from 16 separate study populations. Results from these studies are summarized in Table 2 (full scale IQ and GCI), Table 3 (performance IQ), and Table 4 (verbal IQ). Within each table, results are grouped according to the age at blood-lead measurement and age at outcome measurement; each grouping displays results sorted according to the measure of central tendency of the blood-lead distribution. Because some studies used linear models (BLLs were untransformed) and some used log-linear models (BLLs were log transformed), estimated regression coefficients were, when possible, used to calculate the estimated change in IQ or GCI corresponding to a blood lead increase from 5 to 15 \( \mu \)g/dL to allow for comparisons across studies. Covariates included in adjusted models are grouped into several broad domains that were addressed in most of the published studies.

Among studies that provided results for the size and direction of the associations between BLLs and Full Scale IQ or GCI, regardless of statistical significance, a majority revealed that both crude and adjusted associations were consistent with an adverse effect – IQ decreases with increasing levels of blood lead. In most cases, covariate adjustment attenuated, but did not eliminate, these estimated associations. Findings for performance and verbal IQ were similar, with some studies showing stronger associations of lead with performance IQ and others with verbal IQ.

Notable exceptions to this pattern, however, were found. Results from the Cleveland cohort (Ernhart et al. 1987, 1988, 1989) indicated a crude inverse association between blood lead and IQ but no association with covariate adjustment. In the Cincinnati and Boston cohort studies, BLLs measured at or below 12 months of age showed no association or a slightly positive association with covariate-adjusted IQ (Dietrich et al. 1993; Bellinger et al. 1992). Though published results from a cohort study in Costa Rica (Wolf et al. 1994) did not provide the size and direction of the estimated blood lead-IQ slope, unpublished results provided to the WG did show covariate-adjusted IQ increasing with BLL (B. Lozoff, personal communication 2003). The estimated BLL-IQ association in the Kosovo cohort was strengthened substantially with covariate adjustment (Wasserman et al. 1997).

No trend toward attenuation of the association between blood lead and IQ (or GCI) across studies with decreasing average BLLs is evident (Figures 2 and 3). In one of these studies, analyses were presented that provide more direct information concerning the association between BLL and cognitive function at BLLs <10 : g/dL. The steepest estimates of blood lead-IQ slope from the Rochester (Canfield et al. 2003) studies were based on analyses restricted to children whose measured BLL never exceeded 10 : g/dL. The estimated slope was substantially larger than those estimated from the entire study population (9.2 versus 5.3 IQ point reduction in covariate adjusted IQ for BLL increase from 5 to 15 : g/dL). Canfield and his colleagues (2004) also reported a non-linear model supporting a steeper blood lead-IQ slope at lower levels. Though published as a letter to the editor, rather than in a peer-reviewed article (and therefore
not included in the structured review), similar findings were reported for a reanalysis of the Boston cohort: a steeper BLL-IQ slope in the population of children whose measured BLLs never exceeded 10 µg/dL, compared with the entire study population (Bellinger et al. 2003).

Most of the published studies included at least one measure of socio-economic status. All of the published results from cohort studies were adjusted for Home Observation for Measurement Environment (HOME) score and birth weight; all except the Costa Rica cohort were adjusted for a measure of maternal intelligence. A reanalysis of the data from the Costa Rica cohort with adjustment for maternal IQ was consistent with the original finding of a non-significant positive blood lead-IQ slope (B. Lozoff, personal communication, 2003). Prenatal exposure to maternal smoking was adjusted in the majority of studies, whereas only in the Port Pirie cohort was a measure of postnatal environmental tobacco smoke exposure included. Iron deficiency anemia was included as a covariate in results from the Costa Rica study, which found no association of lead and IQ; the inverse blood lead-IQ associations in the Rochester study (Canfield et al. 2003) and the Karachi study (Rahman et al. 2002) were adjusted for serum transferrin saturation and hemoglobin, respectively. In addition, in the Kosovo study (Wasserman et al. 1997), alternative models were fit with adjustment for hemoglobin, resulting in no appreciable change in the lead coefficient.

Not all studies reported regression coefficients that could be used to estimate the change in IQ associated with a BLL change of 5 to 15 µg/dL, and the overall pattern of results summarized above and in Figures 2 and 3 might have been altered had regression coefficients been available from all studies. For example, a member of the WG provided results of reanalysis of the data from the Costa Rica cohort, which showed no evidence of an inverse relation of BLL to IQ with adjustment for maternal IQ and other covariates used in the published result (Wolff et al. 1994; B. Lozoff, personal communication, 2003).

Studies of Health Endpoints Other than IQ and CGI

More stringent criteria were required for inclusion of studies in this review if they assessed health endpoints other than general intelligence as measured by IQ or GCI. These studies are summarized in Table 5 and are described in the following paragraphs.

Cognitive Function

Lanphear et al. (2000) analyzed data on BLLs on performance on standardized tests of cognitive function of 4,853 children age 6 through 16 years who were evaluated as part of the NHANES III survey, a multiphasic health interview and examination survey of a stratified probability sample of the U.S. population, carried out from 1988 through 1994. In this population, with a geometric mean BLL of 1.9 and 98% of children having BLLs <10 µg/dL, significant inverse relations were found between BLLs and scores on the Wide Ranging Achievement Test (WRAT) arithmetic and reading scores and on the WISC-R block design and digit span subscales. The relationships were strengthened (the slopes became more negative) as analyses were progressively restricted to children with lower BLLs. Stone et al. (2003) reanalyzed the data used by Lanphear et al. (2000). While the results they present are largely consistent with the findings of Lanphear et al., they provided a critique of the validity of the
A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

NHANES III data for evaluating lead-related impacts on neuropsychological development in children. Their critique did not provide results that could be summarized in the structured abstract formant used in this report, so a discussion of the Stone et al. critique is found in Appendix B.

Other Neurobehavioral Measures and Visual Function

Three reports (Altman et al. 1998; Walkowiak et al. 1998; Winneke et al. 1994) describe the relation of blood lead to several neurobehavioral measures and to visual function assessed in 384 school children 5 to 7 years of age in three cities in Eastern Germany. Blood lead levels were generally low, with a geometric mean of 4.25 µg/dL and 95 percent of children having BLLs <10 µg/dL. Walkowiak et al. (1998) reported a significant negative association between BLLs and WISC vocabulary subscale scores. Continuous performance test false positive and false negative responses increased with increasing BLLs. Other measures inversely related to BLL included performance on a pattern comparison test, finger tapping speed (Winneke et al. 1994), and visual evoked potential interpeak latency (Altman et al. 1998). Mendelsohn and colleagues (1999) found a 6 point deficit in the Mental Developmental Index (MDI) of the Bayley Scales of Infant Development for children aged 12 to 36 months with BLLs 10-24 µg/dL compared with children who had BLLs <10 µg/dL. A scatterplot of covariate-adjusted MDI versus blood lead suggests the association continues at BLLs <10 µg/dL.

Neurotransmitter Metabolite Levels

Among children ages 8 through 12 years with mean BLL of 3.95 µg/dL, a direct relation of blood lead (PbB) to higher urinary homovanillic acid, a neurotransmitter metabolite, was found for the subset of children with BLLs >5 µg/dL (Alvarez Leite et al. 2002).

Growth

Two studies examined the relation of BLLs <10 µg/dL to somatic growth. Ballew et al. (1999), using the NHANES III data, found that BLLs were inversely related to height and to head circumference among children 1 to 7 years of age. A birth cohort of children in Mexico had BLLs and head circumference assessed every 6 months from 6 to 48 months of age, during which time the median BLL varied from 7 to 10 µg/dL (Rothenberg et al. 1999). Most postnatal blood lead measures were inversely correlated with covariate adjusted head circumference, with the strongest relation found between blood lead at age 12 months and head circumference at 36 months. Kafourou and colleagues (1997) reported a significant negative association between BLL and covariate-adjusted head circumference and height in a population of children with a median BLL of 9.8, with a scatterplot suggesting the relation extends to BLLs <10 µg/dL.

Sexual Maturation

Two studies, both based on analyses of the NHANES III data, found an association between BLLs <10 µg/dL and later puberty in girls. Selevan et al. (2003) found that BLLs of 3 : g/dL, compared with 1 : g/dL, were associated with significant delays in breast and pubic hair
development in African American and Mexican girls. The trend was similar, but not significant, for non-Hispanic white girls. Age at menarche was also delayed in relation to higher BLLs, but the association was only significant for African-American girls. Wu et al. (2003) reported similar findings for girls in the NHANES III population but did not stratify the analysis by racial/ethnic group. Compared with BLLs 2.0: g/dL and below, BLLs of 2.1-4.9: g/dL were associated with significantly lower odds of attaining Tanner 2 stage pubic hair and menarche; whereas no overall association with breast development was noted.

**Dental Caries**

In the NHANES III population, the odds of having dental caries, comparing children age 5 to or through 17 years in the middle tertile of the BLL distribution (range of BLLs 1.7-4.1) with those in the lowest tertile, was significantly elevated (odds ratio = 1.36, 95% confidence interval 1.01-1.83) (Moss et al. 1999). Gemmel et al. (2002) evaluated the association between BLLs and caries in 6-10 year old children from urban communities in eastern Massachusetts (mean BLL=2.9: g/dL) and a rural community (mean BLL=1.7: g/dL) in Maine. They found a significant direct relation of BLL to caries in the former, but not the latter population in which a non-significant decrease in caries’ frequency was observed with increasing blood lead. In the urban population, the trend of increasing caries with PbB level was evident comparing children with BLLs of 1, 2, and 3: g/dL.

**Blood pressure and renal function**

Among 66-month-old children in Kosovo, a graph depicting adjusted mean systolic and diastolic blood pressure versus BLL showed no consistent trend across 4 groups of children (approximately 28 per group) with BLLs spanning a range from approximately 5 to 10: g/dL (Factor Litvak et al. 1996). In a population of 12- to 15-year-old children living near a lead smelter and a control group, urinary retinal binding protein (U-RBP) was found to be significantly associated with BLL in a stepwise regression. When urinary RBP excretion was examined by BLL tertiles, significantly lower U-RBP was seen in the group with BLL < 8.64: g/dL compared with BLLs 8.64-12.3.

**Heme synthesis biomarkers**

Roels et al. (1987) studied the relations of PbB to heme synthesis biomarkers and reported no evident threshold for inhibition of aminolevulinic acid dehydratase synthesis at PbB as low as 8-10: g/dL, while the threshold for increasing erythrocyte protoporphyrin levels was evident in the range of 15-20: g/dL, consistent with other studies, including two meeting criteria for inclusion in this report (Rabinowitz et al. 1986; Hammond et al. 1985).
Discussion

**Question 1:** Does available evidence support an inverse association between children’s blood lead levels in the range <10 µg/dL and children’s health?

The weight of available evidence, both indirect and direct, clearly favors an inverse association between these BLLs and cognitive function among children. The indirect evidence comes from the great majority of studies that have examined BLLs in relation to standardized measures of overall cognitive function; these studies reveal an inverse relationship and no trend toward weaker associations in populations with lower BLL distributions. More direct evidence of such an association comes from a recent analysis of data from a cohort designed from the start to study the relation of blood lead to child development (Canfield et al. 2003). This study demonstrated that the inverse relation between BLL and cognitive function exists and is stronger at BLLs <10 µg/dL compared with higher BLLs; it also does not show a threshold within the range of routinely measured BLLs below which no association was present. A recent letter to the editor described a reanalysis of the Boston cohort data (Bellinger et al. 2003) with findings consistent with Canfield et al. Several recent analyses of data from the NHANES III and other populations also provide direct evidence of associations that imply adverse impacts of lead on indicators of children’s neurocognitive development, stature, head circumference, dental caries, and sexual maturation in girls, occurring at measured BLLs <10 µg/dL. Though the number of studies providing direct evidence of associations at BLLs <10 µg/dL is limited and most are cross-sectional, they provide supporting evidence of an association in the context of the much larger number of studies that relate slightly higher levels of lead in blood to impairments of children’s health.

**Question 2:** Are the observed associations likely to be causal?

Though the weight of evidence favors an association between children’s BLLs in the range <10 µg/dL and health and, indeed, suggests that such relationships become steeper as BLLs decrease, the work group considered a number of concerns that must be addressed in judging whether such associations are likely to be causal. The work group concluded that collectively, these concerns and limitations of the available evidence preclude definitive conclusions about causation and leave considerable uncertainty concerning the magnitude and form of causal relations that may underlie these associations. At the same time, available evidence does not refute the interpretation that these associations are, at least in part, causal. These issues are discussed individually in the following text, followed by overall conclusions.

**Biologic Plausibility**

Evidence from experimental animal and in vitro studies, which are not subject to confounding influences of concern in human observational studies, can establish causation and identify mechanisms that might be operative in humans assuming a suitable animal model. Thus, evidence from experimental animal and in vitro studies can help to assess potential dose-response relationships and thresholds within the context of any uncertainty added due to interspecies extrapolation. Therefore, an important consideration in judging whether
associations between BLLs <10 µg/dL and health outcomes are likely represent causal relationships is whether such relationships are biologically plausible on the basis of experimental animal and in vitro studies. These studies can also help to assess potential dose-response relationships and thresholds, but extrapolation from in vitro and animal models to human health risk adds additional uncertainty.

Lead is the most extensively studied environmental neurotoxicant. Animal and in vitro studies have provided abundant information concerning biochemical and physiologic changes caused by lead. Along with clinical and epidemiologic data, this evidence has clearly established that lead is toxic to the developing and mature nervous system. These data have been extensively reviewed elsewhere (USEPA 1986; ATSDR 1999; WHO 1995; Davis et al. 1990) and are not exhaustively reviewed here. Rather, this discussion highlights evidence concerning potential mechanisms of lead toxicity and data from animal studies that are relevant to the biologic plausibility of the toxicity of lead, especially to the developing nervous systems of children exposed at BLLs <10 µg/dL.

Although the precise mechanisms of action and their relative importance in different manifestations of lead toxicity are not known definitively, in vitro studies demonstrate that lead can interfere with fundamental biochemical processes. At the most basic level, many of the proposed mechanisms of lead toxicity involve binding to proteins and/or interference with calcium dependent processes (Goldstein 1993).

For some of the adverse health effects of lead (e.g., anemia), the lead-associated biochemical changes that contribute to the effect in humans are well understood. Lead interferes with heme synthesis in part by binding to sulphydryl groups in the enzyme amino levulinic acid dehydratase (ATSDR 1999), which is especially sensitive to inhibition by lead (less than 0.5 micromoles per liter in vitro) (Kusell et al. 1978; Dresner et al. 1982). This inhibition causes delta amino levulinic acid, a potential neurotoxic agent, to accumulate. Lead also inhibits ferrochelatase, an enzyme catalyzing the incorporation of iron into protoporphyrin to form heme. This inhibition also may involve lead binding to protein sulphydryl groups.

Although anemia and accumulation of protoporphyrin IX in erythrocytes are the most obvious consequence of impaired heme synthesis, this pathway could play a role in lead-related impairment of cellular function throughout the body (USEPA 1986). By interfering with heme synthesis and perhaps by inducing enzymes that inactivate heme, lead can decrease the levels of heme in body tissues (Fowler et al. 1980). A reduction in the body heme pool may impair heme-dependent biochemical processes, such as cellular respiration, energy production, and the function of the cytochrome p-450 monooxygenase system involved in detoxification of xenobiotics and in transformation of endogenous compounds such as vitamin D precursors (USEPA 1986).

For other more complex health effects of lead, such as impaired neurocognitive development and behavior change, a number of plausible mechanisms have been demonstrated in animal and in vitro systems. Lead’s impact on one or more biochemical systems needed for normal brain development and function could account for the neurobehavioral effects observed at low levels of exposure. Especially sensitive to lead in vitro is the activation of protein kinase
Lead C (PKC), a calcium dependent enzyme. Lead binds more avidly to PKC than its physiologic ligand, calcium, causing activation at picomolar concentrations in vitro. (Markovac and Goldstein 1988). The interactions between lead exposure and PKC activity in the brain are complex; chronic lead exposure may reduce activity of PKC associated with cell membranes while increasing cytosolic PKC activity. Lead effects on PKC activity have been proposed to mediate potential impacts of lead on cell growth and differentiation, including that of neural cells (Deng and Poretz 2002), the blood-brain barrier, and long-term potentiation (a process related to memory) (Hussain et al. 2000). Lead also interferes with calcium-dependent control of neurotransmitter release at presynaptic nerve terminals; it may thereby interfere with signaling between neurons and possibly with development of neural networks. In both animal and in vitro studies, lead has been demonstrated to interfere with neurotransmitter systems, including interfering with dopamine binding and the inhibition of N-methyl-D-aspartate (NMDA) receptor activity.

The large body of evidence from animal studies of lead exposure and neurodevelopment supports a causal effect that is persistent following exposure early in life and that generally parallels human studies in terms of the domains of function that are impaired (WHO 1995). Concerning blood lead-effect relationships, direct cross-species comparisons of BLLs cannot be made (Davis et al. 1990), and most animal studies demonstrating lead-related developmental neurotoxicity involved doses that produced BLLs well above 10 $\mu$g/dL. However, available studies provide strong evidence of adverse effects in animals with BLLs near 10 $\mu$g/dL. It should be noted that BLLs cited in animal studies generally involve mean levels achieved in experimental groups with individual animals varying, sometimes substantially, around that mean.

Non-human primates experimentally exposed to lead early in life demonstrate dose related impairments in learning and behavior (Bushnell and Bowman 1979; Rice 1985; Levin and Boman 1986). One study, involving monkeys dosed during the first 200 days of life to achieve peak BLLs that averaged 25 and 15 $\mu$g/dL, showed deficits relative to control monkeys (average peak blood lead 3 $\mu$g/dL) at age 3 years on “discrimination reversal” tasks (the animals are taught to respond to a cue and then the cue is changed and the ability to learn the new cue, with and without irrelevant cues, is measured). At the time of testing, mean BLLs in the exposed groups had fallen to 13 and 11 $\mu$g/dL, respectively. Both exposure groups showed deficits, but deficits in the lower exposed group were evident only with more complex tasks (e.g., including irrelevant cues) (Rice 1985). The same monkeys showed persistent impairments at 9 to 10 years of age (Gilbert and Rice 1987). Experimental studies in rats have demonstrated behavioral effects at mean BLLs in the range of 10-20 $\mu$g/dL (Cory-Slechta et al. 1985; Brockel and Cory-Slechta 1998).

There is uncertainty about the relationship of the tissue or cellular levels of lead linked to physiologic changes in animal and in vitro studies to the corresponding human blood lead level required to produce such levels at target sites. Although most (90 to 99%) lead in whole blood is in red cells, plasma lead level likely better reflects lead transferred from bone stores and available for transfer to target tissues (Cake et al. 1996). Because red cells have limited capacity to accumulate lead, the relation of blood lead to plasma or serum lead is non-linear with serum lead increasing more rapidly at higher BLLs (Leggett 1993). In subjects with a mean BLL of 11.9 $\mu$g/dL, plasma lead levels ranged from 0.3% to 0.7% of whole BLLs (Hernandez-Avila et
The relation of plasma serum levels in intact animals to tissue levels measured in in vitro models is probably more complex. It is also uncertain whether in vitro studies demonstrating possible mechanisms for low-level lead toxicity reflect mechanisms operative in the intact animal. For example, Zhao et al. (1998) found that lead interfered with PKC in choroid plexus endothelial cells in a dose dependent fashion over the concentration range of 0.1-10 micromolar. However, no effect on choroid plexus PKC activity was seen in an in vivo model.

Conclusions: The fundamental nature of biochemical and physiologic changes linked to lead in in vitro and experimental animal studies illustrates potential mechanisms for lead toxicity that might be operative in humans at very low exposure levels. Experimental animal studies support the biologic plausibility of adverse health effects of lead in children at BLLs near 10 µg/dL. However, definite conclusions concerning the relationship of health status of children and BLLs <10 µg/dL cannot be drawn from these studies because of limitations of extrapolating from in vitro systems to intact animals and from animals to humans and because of the limited amount of data available from studies of animals dosed to produce a range of BLLs less than 10 µg/dL. Data from primates, which can most readily be extrapolated to humans, are especially limited.

On the other hand, given the uncertainty in extrapolating across species, the fact that animal test systems cannot match the complexity of learning tasks faced by young children, and the relatively small relative difference in BLLs shown to be harmful in animals and those at issue in children, adverse health effects in children at BLLs <10 µg/dL are biologically plausible.

Blood Lead Measurement

The precision and accuracy of blood-lead measurements performed in an epidemiologic study impacts observed results. If BLLs are systematically over or underestimated, biases in estimated blood lead response relationships and/or no effect thresholds will result. All blood lead measurements involve some random error, which, if a true association between blood lead and health exists, will tend to bias estimates of the relation toward the null (i.e., no effect) value. The quality of blood lead measurements varies between laboratories, between different analytical technologies, and between different specimen collection techniques. In addition, laboratory performance for blood lead has improved markedly over the last three decades and continues to improve as new analytical technologies are developed. Each of these factors becomes important in assessing the quality of blood-lead measurements used in published studies. In this section, specimen collection and laboratory factors that can affect blood-lead precision and accuracy are considered.

The widespread industrial use and dispersal of lead, particularly during the last century, has ensured that it is a ubiquitous contaminant. Therefore, to prevent false-positive results, stringent procedures are necessary to reduce environmental contamination of blood collection devices and supplies. Consequently, venous blood collected using evacuated tubes and needles certified as “lead-free” is considered the most appropriate specimen for blood lead measurements (NCCLS 2001). However, collection of venous blood from pediatric subjects is sometimes difficult; thus, capillary blood from a finger puncture is used widely for screening purposes.
Published studies have compared the quality of blood lead results for capillary and venous specimens drawn simultaneously (Schlenker et al. 1994; Schonfeld et al. 1994; Parsons et al. 1997). With stringent precautions, particularly rigorous hand washing, contamination errors can be held to <4 percent (Parsons et al. 1997). Therefore, although venous blood is preferable for epidemiologic studies of environmental lead exposure, use of capillary blood is acceptable if collected by staff specially trained in the technique using devices certified as “lead-free.” Data should be provided showing an acceptably low rate of contamination errors and low mean bias in the capillary BLLs as collected using the study protocol.

Currently, three analytical approaches to blood lead measurement are used: atomic absorption spectrometry (AAS); anodic stripping voltammetry (ASV), and inductively coupled plasma mass spectrometry (ICP-MS). A thorough discussion of these analytical techniques is beyond the scope of this report; however, a comprehensive assessment has been published by the National Committee for Clinical Laboratory Standards (NCCLS 2001). Briefly, the older flame atomization AAS methods, which include MIBK-extraction and Delves cup, are less precise, with a detection limit near 5 µg/dL for Delves cup (Parsons et al. 1993). Thus, they are not well suited for examining relationships between BLLs <10 µg/dL and health. The electrothermal atomization techniques based on the graphite furnace (ETAAS) are more precise and more sensitive and, therefore, have better detection limits, typically around 1.0 µg/dL. A direct comparison between ASV and ETAAS techniques (Bannon et al. 2001) shows that the latter has better precision and better accuracy. Nonetheless, when operated in experienced hands and with a stringent quality assurance/quality control (QA/QC) program that includes calibration standards traceable to the mole via isotope dilution mass spectrometry (ID-MS), ASV can deliver blood-lead measurements with accuracy and precision sufficient to examine health effects at BLLs <10 µg/dL (Roda et al. 1988).

In order to assess the accuracy and precision of blood-lead measurements made for research purposes, investigators should provide information on the laboratory’s performance in measuring external quality control samples and on the between-run standard deviation for routine quality control samples that span the relevant blood lead range for a given study.

**Conclusions:** The key considerations relevant to judging the accuracy and precision of blood lead measurements in published studies include the type and quality of blood specimen collected, analytical methodology used by the laboratory, and internal and external QA/QC procedures in place. For the purpose of studying the relationship between BLLs <10 µg/dL and health endpoints, venous samples are preferred and capillary samples are acceptable with evidence of a rigorous protocol to control contamination errors. Acceptable analytic methods include electrothermal AAS, ASV, and ICP-MS. Information on laboratory performance (i.e., accuracy and precision) from external and internal quality control data should be provided.

To be included in this review, studies were required to have employed suitable measurement methods. In addition, venous samples were used for most postnatal blood lead measurements in the relevant cohort studies (Table 6) and others cited in this report. Given this and the blood lead quality control procedures reported in the most informative studies, it is highly unlikely that systematic errors in measurement in the relevant studies were sufficient to bias the observed blood lead distributions enough that associations observed in the range <10
µg/dL were attributable to BLLs above that threshold. Random variation in BLLs and random error in BLL measurement would make it difficult to collect sufficient data to identify a threshold, if one were to exist.

**Blood Lead Age Trend, Tracking, and Inference Concerning Blood Lead — Effect Relations in Children**

Age-related changes in children’s BLLs and within-child correlation of blood lead measured at different ages may influence observed associations between BLL and health at a given age. In addition, the biologic impact of lead in children is likely determined not only to the BLL measured at any one time but, also, the ages at which a given level occurs and the duration of exposure.

Under most exposure scenarios, children’s BLLs show a characteristic age trend. A newborn’s BLL will largely reflect the BLL of its mother. Because adult women tend to have lower BLLs than young children, umbilical cord BLLs are generally lower than BLLs during childhood. During the latter half of the first year of life, however, children’s BLLs begin to increase as the infant becomes more active, mobile, and exposed to ambient lead. The onset of ambulation during this period is likely to be important, as are play patterns that bring the child into contact with environmental media such as lead-contaminated dust and soils. Other factors that affect exposure include the increased hand-to-mouth activity of children, including the practice of eating “in place,” i.e., in play areas. Physiologic factors, such as more efficient absorption of ingested lead in children compared with adults, and their greater food and air intake on a body weight basis might also contribute to the early postnatal rise in BLL.

The mean BLL within a study sample generally peaks during 18 to 36 months of age, and slowly declines over the next few years. This blood lead profile is seen among economically disadvantaged urban minority children (Dietrich et al. 2001) and among children living near lead smelters (Figure 4) (Tong et al. 1996). In cohorts with extremely high exposures, the blood lead decline might be very gradual (e.g., Wasserman et al. 1997). In the Cincinnati Study, the same general profile was evident in each of four strata defined by average lifetime BLL, suggesting that it is, to some extent, independent of the overall level of exposure. This blood lead profile has not been observed in all study cohorts, however. In the Boston Study, for example, mean BLL varied minimally, from 6.2 to 7.6, from birth through 5 years of age (Rabinowitz et al. 1984; Bellinger et al. 1991).

One implication of the typical profile is that maximum level is often associated with age, constituting an obstacle to an effort to identify age-specific vulnerability to lead toxicity. Compounding this challenge is that, under many exposure scenarios (particularly those involving higher exposures), intra-individual stability of BLL tends to be substantial. That is, BLL tends to “track,” so that if, at time 1, child A has a higher BLL than child B, child A is likely to have a higher BLL than child B at time 2 as well. Thus, children’s rank ordering tends to be similar over time even though, in absolute value, BLL rises and falls over the course of childhood. Again, however, the degree of intra-individual stability varies from cohort to cohort. In the Boston Study cohort, for instance, the extent was limited; this stability is likely attributable to the generally low BLLs of the study population (Rabinowitz et al. 1984).
A BLL measured after 36 months of age will, on average, be lower than the BLL that would have been measured if a child’s blood been sampled sometime during the 18 to 36 month period. Suppose, however, that the critical period with regard to producing an adverse health outcome is the 18 to 36 month period, and that, in a study conducted post-36 months, an inverse association is noted between concurrent BLL and a health endpoint. If the concurrent BLL is the only index of lead exposure history available, basing a dose-effect assessment on it will, to the extent that the natural history of BLLs in the study cohort follows the canonical form illustrated above, result in an underestimate of the BLL responsible for any adverse health effects noted at the time of or subsequent to blood sampling. In other words, one will conclude that adverse health effects occur at lower BLLs than is the case. For instance, assume that the inverse association shown in Figure 5 holds between IQ and concurrent blood lead in a cross-sectional study of 6 year olds.

If, however, the BLL of each child was, on average, 5 µg/dL greater at age 2 than at age 6, and age 2 is the time of greatest toxicologic significance (i.e., it is age at which lead exposure produced the IQ deficit observed at age 6), then the dose-effect relationship that underlies the association seen at age 6 would be more accurately described as in Figure 6. This dataset would thus not be informative with respect to the functional form of the dose-effect relationship at levels below 10 µg/dL insofar as (hypothetically) all children had a BLL greater than 10 at age 2.

Other uncertainties apply to interpreting blood lead-health associations (or lack of associations) observed at any point in time. First, the relation of age to vulnerability to lead toxicity is not well understood. Is BLL during the age period 18 to 36 months more toxicologically critical than a measure of cumulative lifetime exposure, such as the area under the curve or some other exposure index? Also, it is possible that the critical age varies with dose, health endpoint, or sociodemographic factors. Available studies do not provide consistent answers to these questions. For example, in the Boston cohort, blood lead at age 24 months was most strongly related to IQ at age 10 years (Bellinger et al. 1992), whereas in the Port Pirie Cohort, the lifetime average BLL through age 5 years was most predictive of IQ at age 11 to 13 years.

If 18 to 36 months is the critical age of exposure, theoretically, it is possible to “adjust” an observed blood lead distribution measured at age 6 by some function to reflect the downward trend in BLL with age and estimate the blood lead distribution at a different age, (e.g., age 2 years). However, a “one size fits all” adjustment likely is not appropriate for all children. Moreover, the appropriate adjustment is likely to be study-site-specific (i.e., depend on the key exposure sources and pathways of a particular study cohort).

It would be possible to get a general sense of how accurately past peak exposure can be estimated for children in cross-sectional studies by using data collected in prospective studies in which blood lead was measured frequently during the period spanning birth to school-age. Examining the distribution of the differences between BLLs measured at ages 18 to 36 months.
and at age 6 would suggest the amount of exposure misclassification that would result from applying a constant adjustment factor.

**Conclusions:** Because of age trends in blood lead and the tendency of BLLs to “track” within individual children, inferences drawn from cross-sectional associations between blood lead and health at a given age should be interpreted cautiously because of the influence of likely higher BLLs occurring earlier in life. It may be possible to apply data on age trends and within-subject correlation of blood lead to estimate, from an observed blood lead – health association, the approximate relation to BLLs at an earlier age. However, because of differences between study populations in age trends and “tracking,” any estimate of the earlier blood lead distribution will have considerable uncertainty. If the only relevant studies available are based on cross-sectional data (e.g., data from NHANES III), age trends and “tracking” of BLLs would represent a substantial challenge to inferring a causal link between BLLs <10 µg/dL and adverse health impacts. However, recently published results from two cohort studies (Canfield et al. 2003; Bellinger et al. 2003) showed inverse associations between BLLs measured early in life (6 to 24 months and 24 months, etc.) and IQ measured at older ages among children whose measured BLLs did not exceed 10 µg/dL. Therefore, associations observed in cross-sectional studies cited in this report likely do not exclusively result from the impact of higher BLLs experienced earlier in life.

**Quality of Neurobehavioral Assessments**

As with blood lead (exposure) measurements, the accuracy, precision, and consistency of neurobehavioral assessments can influence observed blood lead-outcome relations. In order to judge whether the data from a study should be considered in characterizing the functional form of the dose-effect relationship at BLLs below 10 µg/dL, one would like to have access to the following information about the conduct of the neurobehavioral assessments:

- **Assurance that examiners were blinded to all aspects of children’s lead exposure histories.**
- **The assessment setting.** Assessments can be standardized when carried out in a hospital, neighborhood health center, or community center, but may be difficult to standardize in a participant’s home.
- **Essentials of the process by which an examiner was trained, including the criterion used to certify an examiner (e.g., percent agreement on an item-by-item basis with some gold standard, average difference in scores assigned compared with gold standard, correlation with gold standard in terms of scores assigned).**
- **The plan implemented for supervision of test administration over the course of data collection (e.g., periodic observation of test sessions, live or by videotape).**
- **The plan implemented for supervision of test scoring over the course of data collection (e.g., double scoring of a sample of protocols).**
• The number of neurobehavioral examiners used over the course of data collection.

• If more than one assessor was used, whether the data analysis plan included evaluation of an “assessor” effect (i.e., as a main effect and as a modifier of lead’s association with endpoints).

While some have argued that neurobehavioral examiners should have professional qualifications (e.g., Kaufman 2001 cites the need for a clinician with graduate-level training in psychometrics, neuropsychology, etc.), the Practice Committee of the American Academy of Clinical Neuropsychology supports the widespread practice of using non-doctoral level personnel, with appropriate training and supervision by a doctoral-level psychologist, in the administration and scoring of clinical neuropsychological evaluations (Brandt et al. 1999).

Assuming examiners are blinded regarding BLLs, most problems with quality of neurobehavioral assessment would be expected to mask or underestimate true associations rather than create spurious ones. It is possible, for example, that use of non-professional examiners might introduce noise into the data, masking an association between toxicant exposure and performance. In one study of methylmercury (MeHg) exposure (Grandjean et al. 1997), MeHg was inversely associated with children’s scores on the Similarities subtest of the WISC-III among children tested by the supervising doctoral-level study examiner. Assuming that blinding was preserved, use of non-professional examiners likely would not introduce a positive bias in effect estimates.

Measurement quality problems causing bias of associations away from the null, without loss of blinding, are theoretically possible. For example, if one examiner consistently yields lower scores than another and that examiner, without knowledge of BLLs, is assigned to assessments of a segment of the study population at higher risk for lead exposure, a spurious inverse association could be created between lead level and neuropsychological test scores.

**Conclusions:** The key considerations in judging the quality of neurobehavioral assessments in the research setting are the blinding of examiners to lead-exposure history, the training and supervision of examiners, and the setting for examinations. If examiners are truly blinded, other data quality problems generally will bias estimated relationships between blood lead and outcomes toward the null. Therefore, given that examiners were blinded to BLLs in cohort studies demonstrating associations (Table 6) and the NHANES III survey, errors in measurement of neuropsychological function likely did not contribute to observed associations with BLLs <10 µg/dL.
Potential Confounding Factors

Social Factors

Socioeconomic factors influence both lead exposure and many health outcomes, including intellectual development, growth, and a number of chronic conditions, creating the potential for social factors to confound associations between children’s lead exposure and health in observational studies. Because cognitive function as reflected in measured intelligence is strongly associated with socioeconomic status (SES) and because cognitive function in children is the most studied health endpoint in studies of lead-exposed children, this discussion is focused on possible SES confounding of associations between BLL and measured intelligence. The potential for reported subtle effects of lead on IQ and related measures of intellect to be attributable to confounding by socioeconomic factors warrants serious consideration (Bellinger et al. 1989). Key relations required for confounding to occur are almost certainly present – SES has been shown to be related to BLLs, presumably because the neighborhoods and homes in which families of lower income reside are associated with higher levels of lead in soil and residences. Socioeconomic status also is clearly related to measures of intelligence, whether through parental stimulation, nutrition, or resources available in the home. With an inverse relationship between socioeconomic factors and lead levels (i.e., higher SES predictive of lower lead levels) and a positive relationship between socioeconomic factors and measures of intelligence (higher socioeconomic status predictive of higher intelligence test scores), failure to adjust for the confounding effect of socioeconomic factors will result in confounding that overstates the harmful effect of lead on IQ because the socioeconomic effect will be mixed with any true effect of lead exposure. In addition, confounding by social factors may be a concern for some other lead-associated health measures with social gradients such as height (Silventoinen 2003).

Data presented from most of the key studies included in this review strongly suggest that substantial confounding by socioeconomic factors occurs. Even with adjustment for crude measures (e.g., parental education and household income) (Lanphear et al. 2000), the apparent lead effect on cognitive function is greatly reduced. Such a pattern in which adjustment for a crude proxy results in a substantial decrement in the magnitude of association would suggest that “residual confounding” may be present in the adjusted estimate of effect. If residual confounding is indeed present, then tighter control for confounding with more refined measures of the social environment may further attenuate or eliminate the apparent effect (Savitz et al. 1989).

The following factors complicate this scenario:

1. Socioeconomic status is a very elusive construct to fully capture; it is far more complex than is reflected in parental education or income. Socioeconomic status includes many aspects of economic means and associated lifestyle, so that adjustment for operational measures, such as education or income, will always be incomplete. Adjustment for an imperfect proxy measure of a confounder results in residual confounding (Greenland et al. 1985; Savitz et al. 1989).
2. Long-term lead exposure is imperfectly reflected in a current blood lead measure or to some extent, even from a series of blood lead measures (see Blood Lead Tracking) (Bellinger et al. 1989). Whatever physiologic effect lead might produce, available evidence suggests that the impact is chronic and cumulative. Beyond what is reflected in a blood-lead measure, SES may be indicative of historical exposure; thus, the observed effect of socioeconomic status would partly reflect an effect of lead exposure above and beyond the blood-lead measure.

The nature and magnitude of these associations is less clear when focusing on BLLs <10 µg/dL. Measures of social advantage, including income and parental education, are associated with BLLs <10 µg/dL (e.g., Lanphear et al. 2000). However, the relative importance of different aspects of socioeconomic status and the pathways by which they affect lead exposure are not entirely clear. The association between lower income and deterioration of paint in older housing contributes to variation in BLLs, even BLLs <10 µg/dL. The increase in geometric mean blood lead associated with living in an older home is greater for children from low-income families than for those from middle income families (Pirkle et al. 1998). Nonetheless, with the elimination of lead in gasoline and the continued decline in the proportion of homes with leaded paint (Jacobs et al. 2002), the relative importance of lead exposure sources possibly is changing. It is also possible that the association of social factors with lead exposure is different for populations with BLLs <10 µg/dL than for those above that level.

Several strategies have been applied to address the role of socioeconomic factors and isolate a non-specific effect of socioeconomic factors on IQ from an effect of lead exposure. First, populations can be sought or even constructed in which blood lead is not closely associated with socioeconomic status as demonstrated most clearly in the Boston cohort (Bellinger et al. 1987). In that population, all in a relatively low blood lead range for that time and the great majority of relatively advantaged socioeconomic status, there was a weak positive gradient between socioeconomic status and lead. The Kosovo cohort (Wasserman et al. 1997) also departed from the usual trend in that the more socioeconomically advantaged of the two communities studied was the site of a lead smelter. As a result, adjustment for social and other covariates actually strengthened the inverse relation of blood lead to IQ in that population.

Second, improved measures of socioeconomic factors have been applied to better control for non-specific effects. That is, by refining and decomposing the construct of socioeconomic status, it is possible to adjust more fully for the confounding dimensions such as nutrition, parental stimulation, attitudes towards achievement, etc., and not adjust for the aspects that primarily serve as a proxy for lead exposure, such as age of housing and neighborhood. One example among published research of refining and decomposing the construct of socioeconomic status has been the use of the HOME scales to adjust for stimulation provided by caregivers. Use of HOME scales has in some cases further attenuated but not eliminated apparent lead-IQ associations.

A third approach to examine the possibility of confounding of the blood lead-IQ relation at low levels would be to conduct a formal statistical assessment of the extent to which the strength of the observed association across studies varies in relation to control for relevant confounders, using meta-regression, as was applied by Schwartz (1994). This approach could be
refined to assess possible residual confounding. One challenge in performing such an analysis using published summary data is the difficulty in operationalizing measures of the tightness of SES adjustment while controlling for other aspects of study design that might influence blood lead- IQ slopes. An alternative approach is discussed later in this report (see Research Needs).

**Conclusions:** On the basis of available evidence the observed associations between blood lead below 10 µg/dL and cognitive function likely do not entirely result from confounding. This conclusion is supported by the following: evidence

- The studies showing the strongest relationship (Canfield et al. 2003; Bellinger et al. 2003) at low levels employed the HOME scale for adjustment, which is the best available measure for assessing the impact of the home environment on child development.
- Two cohorts, Kosovo and Boston, in which strong associations were found between blood lead and IQ, were characterized by a direct, rather than inverse, correlation of blood lead with social advantage.
- Diversity of geographic and social settings in which associations of children’s blood lead close to 10 µg/dL and intelligence have been seen.
- Animal data have demonstrated effects of lead at BLLs near 10 µg/dL.

On the other hand, the ability to detect confounding by omitted covariates by comparisons across studies is limited because, for most covariates of potential interest, the number of relevant studies in one group being compared is limited. In other words, for a given covariate, either few studies included it (e.g., postnatal ETS exposure) or few excluded it (e.g., SES). At this point, the case for residual confounding by social environment is speculative, but available studies relating blood lead to cognitive function in children cannot entirely exclude the possibility that observed associations are at least partly influenced by it. Such a possibility does increase uncertainty about the actual strength and shape of blood lead relationships at BLLs less than 10 µg/dL.

**Iron Status**

Nutritional factors, such as iron and zinc intake, that might be correlated with lead uptake and might influence children’s health, could confound associations between BLLs and health from observational studies. The potential for iron deficiency to confound the association between blood lead and neurodevelopmental status has been of most concern and is the focus of this discussion. The likelihood of such bias is dependent upon the extent to which iron status was controlled in a given study and the prevalence of iron deficiency in a study population. Iron deficiency may impair neurodevelopment in a manner similar to low-level lead exposure and the populations at increased risk for iron deficiency and lead toxicity may overlap (Lozoff et al. 1991; Wasserman et al. 1999). However, the association between iron deficiency and blood lead is not consistent across populations (CDC 2002). Therefore, the potential for iron to confound an association of blood lead with neurodevelopmental status will vary across populations, depending on both the prevalence of iron deficiency and its association with blood lead level.

For research purposes adequate assessment of iron status entails determination of hemoglobin or hematocrit and at least two other measures of iron status. Generally accepted definitions of iron deficiency and iron deficiency anemia depend on age- and sex-specific normal
A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

ranges. The iron status measures most commonly used are mean corpuscular volume (MCV), free erythrocyte protoporphyrin (FEP) or zinc protoporphyrin (ZPP), transferrin saturation, ferritin, and, more recently, transferrin receptor. The standard for defining iron deficiency is values indicating iron deficiency on at least two of these measures and/or response to iron therapy with an increase in hemoglobin to at least 10 g/L. The utility of ferritin in young infants is under debate, making it important that functional measures, such as MCV or ZPP be obtained. There are limitations of each measure (e.g., ferritin goes up with infection, MCV is down in hemoglobinopathies, etc.).

Although iron deficiency with low hemoglobin has been associated with later impairment of cognitive function (Grantham-McGregor et al. 2001), it is not certain which measure(s) of iron status are most strongly related to neurodevelopmental outcomes. In studies of children with higher BLLs, controlling for hemoglobin is problematic because lead toxicity can reduce hemoglobin in the normal range or cause frank anemia. This is less of a concern in studies of children with BLLs <10 µg/dL, a range in which no meaningful impact on hemoglobin levels has been observed.

**Conclusions:** Measurement of iron deficiency has been absent or suboptimal in most of the studies reviewed. Two studies in which iron status was controlled for using transferrin saturation (Canfield et al. 2003) and serum ferritin (Lanphear et al. 2000) found strong inverse relationships between blood lead and cognitive function, whereas a third study that controlled for the presence of iron-deficiency anemia found the opposite (Wolf et al. 1994). Furthermore, iron-deficiency anemia is the measure of iron status most clearly linked to impaired cognitive function; therefore, it seems unlikely that the prevalence of iron deficiency anemia could be high enough in the populations showing the strongest inverse relations of blood lead to cognitive function (Canfield et al. 2003; Bellinger et al. 2003; Lanphear et al. 2000) to entirely explain these associations. In the NHANES III data used by Lanphear et al. (2000), the prevalence of iron deficiency ranged from 1% to 9%, depending on the age and sex group (CDC 2002). Finally, in Kosovo, following treatment of iron-deficient children with iron supplements, no association of earlier hemoglobin levels with IQ at age 4 (Wasserman et al. 1994) or age 7 (Wasserman et al. 1997) was found. Thus, iron deficiency likely does not completely explain the inverse associations between BLLs <10 µg/dL and cognitive function.

**Tobacco**

Blood lead levels in children have been associated with exposure to environmental tobacco smoke (assessed by caregiver report or by urinary cotinine levels) in both general population surveys (Stromberg et al. 2003; Mathee et al. 2002; Lanphear et al. 2000; Mannino et al. 2003) and in studies of children living near lead smelters (Willers et al. 1988; Baghurst et al. 1992; Baghurst et al. 1999). The explanation for this association is not entirely clear; possibilities include enhancement of lead uptake by environmental tobacco smoke (ETS), exposure to lead in ETS itself, and differences in cleaning practices or child supervision between households with and without smokers.

Maternal smoking during pregnancy has been associated with behavior problems and impaired cognitive development in children; fetal hypoxia is one possible contributing
mechanism (Habek et al. 2000). Evidence for an effect of prenatal or postnatal ETS exposure on neurodevelopment is less clear (Eskenazi et al. 1999). As with studies of lead and neurodevelopment, social factors may confound, at least in part, the association between maternal smoking and neurodevelopment (Baghurst et al. 1992). A child’s prenatal exposure to maternal smoking or pre- or postnatal exposure to ETS could, if these are causally related to impaired neurodevelopment or other adverse health outcomes, confound the observed associations of lead and health. In addition, if a relationship between postnatal ETS and neurodevelopment is established, lead exposure could be a mediating factor.

**Conclusions:** Of the studies reviewed, most did not assess prenatal or postnatal ETS as a possible confounding factor. Those that assessed tobacco at all controlled for maternal smoking during pregnancy. However, the two exceptions, Lanphear et al. (2000) in which serum cotinine measurements were used to control for ETS and a study based on the Port Pirie cohort (Tong et al. 1996; Baghurst et al. 1992) which reported postnatal parental smoking, provide no evidence that confounding by tobacco exposure accounts for the associations observed between blood lead and adverse health effects. Limitations in available studies leave some uncertainty as to what contribution, if any, ETS might make to observed associations between BLL and health.

**Causal Direction**

Inference of causation from observational epidemiologic studies is sometimes complicated by the possibility that the health outcome under study could be a cause of the exposure or causally related to a third factor which itself is a cause of the exposure under study. Two possibilities—mouthing behavior and calcium balance—are relevant to studies of the health effects of lead at low levels.

**Mouthing behavior**

An important pathway of lead uptake by young children is ingestion of lead-contaminated dust (Charney et al. 1980; Bornschein et al. 1985), presumably through mouthing of hands, surfaces, and objects on which the dust is deposited. Although mouthing behavior is difficult to measure, children with more reported mouthing behavior have higher BLLs in relation to environmental lead exposure (Lanphear et al. 1998; Bellinger et al. 1986; Baghurst et al. 1999). Pica (purposeful ingestion of non-food items) can be a consequence of impaired neurodevelopment and can predispose one to lead ingestion (Cohen et al. 1976; McElvaine et al. 1992; Shannon et al. 1996), but the relation of variation in “normal” age-appropriate mouthing behavior to neurodevelopment is uncertain. However, in groups of children, average measured or caregiver reported mouthing has been shown to diminish with age (Juberg et al. 2001; Tulve et al. 2002). Nonetheless, it is unclear whether, at the individual level, more frequent mouthing behavior is a marker (independent of its effect on lead ingestion) for delayed neurodevelopment. If such behavior is a marker, then an association between blood lead level and impaired neurodevelopment would result, and failure to adjust for mouthing behavior would result in an overestimate of the blood-lead effect. On the other hand, if measured mouthing behavior is associated with cumulative lead exposure above and beyond that reflected in measured BLLs,
then controlling for mouthing behavior could amount to over control, underestimating the true effect of lead on neurodevelopmental measures.

**Conclusions:** At this point, no direct evidence supports reverse causation by mouthing behavior, and this hypothesis remains speculative. Arguing against this possibility, Tong et al. (1996) reported that an early measure of neurocognitive development, the Bailey MDI, was not predictive of later BLLs.

**Calcium balance**

Calcium balance changes in relation to growth during childhood and during the rapid expansion of bone mass during puberty and the pubertal growth spurt (Bronner et al. 1998; van Coeverden et al. 2002; Bailey et al. 2000); estradiol may influence bone mineral deposition in pubertal girls (Cadogan et al. 1998). It is possible that effect of skeletal growth and puberty on calcium balance could cause lower BLLs (Thane et al. 2002), just as the opposite changes in calcium balance during menopause appear to cause an increase in blood lead (Hernandez-Avila et al. 2000; Garrido Latorre et al. 2003). It should be noted that the average age at menarche among U.S. adolescents dropped by approximately 2.5 months between the periods 1963-1970 and 1988-94 and that this trend was accounted for in part by a rising prevalence of obesity (Anderson et al. 2003). Average BLLs were likely falling substantially during this same period.

**Conclusions:** Because human studies linking blood lead at levels <10 μg/dL to delayed puberty and smaller stature are, with one exception, cross-sectional and evidence is limited on this topic, reverse causation via changes in calcium balance cannot be ruled out as accounting for at least some of the observed associations. While the parallel secular trends in decreasing age at menarche and decreasing BLLs could be explained in part to a causal effect of lead delaying age at menarche, it is also possible that other secular trends (e.g. increasing obesity rates) have caused the trend toward earlier menarche.
Overall Conclusions

**Question 1:** Does available evidence support an inverse association between children’s blood lead levels in the range <10 µg/dL and children’s health?

Because of the large number of studies that have assessed cognitive function as an outcome, the review and conclusions by the WG primarily focus on this health domain. The consensus of the WG is that the overall weight of available evidence supports an inverse association between BLLs <10 µg/dL and the cognitive function of children. The evidence for such an association is bolstered by the consistency across both cross-sectional and longitudinal studies in varied settings with blood lead distributions overlapping 10 µg/dL and by the lack of any trend towards a weaker association in studies with lower population mean BLLs. More recent studies and analyses best suited to examining this association (Canfield et al. 2003; Bellinger et al. 2003) have added to, rather than refuted, evidence for such an association noted in prior CDC guidance (1991).

In reaching this conclusion, the WG is mindful of limitations in the available evidence base. Relatively few studies have directly examined the association between BLLs <10 µg/dL and health status among children, and many of those that have are cross sectional studies in which data are unavailable on BLLs earlier in life and key covariates. The WG concluded that findings from numerous published studies relating BLL to cognitive function, while not limited to children with BLLs <10 µg/dL, collectively were not consistent with a threshold for the BLL-cognitive function association at 10 µg/dL. This indirect evidence, however, is less persuasive than cohort studies and analyses that directly assess the relationship between BLL and health in the range <10 µg/dL. These directly relevant studies analyzed data for children whose measured BLLs did not exceed 10 µg/dL (to the investigator’s knowledge). Likely included in these analyses were some children who, because of random variation in BLL or age trends, did at some time have a BLL >10 µg/dL that was not measured. Such misclassification could produce an apparent inverse association between BLLs <10 µg/dL and health status even if a threshold existed at 10 µg/dL. Such misclassification, however, could not account for the observed BLL-IQ relation in the Canfield (2003) study, in which a steeper slope was observed at BLLs <5 than at levels 5-10 µg/dL.

For health endpoints other than cognitive function, including other neurologic functions, stature, sexual maturation, and dental caries, available data are more limited and less replication of findings exists across studies. Nonetheless, the available data from these studies are consistent with associations between higher BLLs within the range <10 µg/dL and poorer health indicators.

**Question 2:** Are the observed associations likely to be causal?

The work group concluded that, while available evidence does not permit a definitive causal interpretation of the observed associations between higher BLLs in the range <10 µg/dL and adverse health indicators, the weight of available evidence favors, and does not refute, the
interpretation that these associations are, at least in part, causal. The WG also concluded that the limitations of the available evidence, including likely residual confounding by social environment, leave uncertainty about the absolute strength and shape of the causal relation at the population level. Even greater uncertainty attends the use of associations observed in the relevant population studies for interpretation of BLLs measured in individual children at a single point in time. Thus, the WG does not believe that the individual children can be classified as “lead poisoned,” as the term is used in the clinical setting, on the basis of the associations observed in studies reviewed for this report. The basis of the overall WG conclusions is discussed below and is followed by a summary of the important limitations in the available evidence.

The WG explored other possible explanations (aside from causation) for these associations and concluded that none are likely to fully explain the observed data. The context of evidence from animal, in vitro, and human studies of adult populations, also supports the consensus of the WG conclusion that the observed associations most likely represent, at least in part, causal adverse impacts of lead on children’s cognitive function at BLLs less than 10 µg/dL.

The greatest source of uncertainty in interpreting the relationship between BLLs <10 µg/dL and cognitive function is the potential for residual confounding by social factors. The conditions for residual confounding appear to be present: BLLs are strongly influenced by SES, SES is clearly related to measured cognitive function, and social factors that could influence BLL and cognitive function are difficult to measure precisely. Other sources of potential bias are, individually, less concerning than social confounding, but collectively they add to the overall uncertainty about the absolute strength and shape of the relation of BLL to impaired cognitive function. These include, random error in blood lead measurement and in a single BLL as a measure of chronic exposure, possible influence of factors that have not been fully addressed in published studies, including blood lead tracking and age trend, which limits cross-sectional studies in particular, tobacco smoke exposure, iron deficiency, and mouthing behavior. Error in measuring lead exposure would bias observed associations towards the null, while failure to adjust for the other factors noted would most likely bias observed associations away from the null.

The recently reported trend of asymptotically increasing slopes of lead-associated decrements in cognitive test scores at lower BLLs (Bellinger et al. 2003; Canfield et al. 2003; Lanphear et al. 2000) would be expected if residual confounding were operative as illustrated in Figure 7. The graph on the left depicts a comparison of two groups of children who live in a high exposure setting. They differ, on average, with respect to aspects of the home and social environment that are not captured in measured covariates. This results in one group ingesting and absorbing twice as much lead and having, after adjustment for measured covariates, a mean IQ 1 point lower than the children raised in a more favorable environment. Assuming a roughly linear relation of lead intake to blood lead, the result is that one group has a mean blood lead twice as high, corresponding to a 10 µg/dL difference in blood lead and an estimated blood lead-IQ slope attributable to residual confounding of 0.1 IQ points per µg/dL. The figure on the right depicts the same hypothetical two populations living in a low exposure setting. The same imperfectly measured differences in social environment contribute to the equivalent covariate-adjusted difference in mean IQ, but in this case, although one group ingests twice as much
contaminated dust as before, lower levels of lead contamination result in the two children having a blood lead difference of only 1 : g/dL in blood lead level. The result is an estimated blood lead-IQ slope attributable to residual confounding of 1.0 IQ points per µg/dL. In addition, a convincing and directly relevant biologic mechanism for such a dose response relation has yet to be demonstrated. Though this hypothetical example cannot demonstrate that residual confounding underlies the steep blood lead-IQ slopes observed at low levels, it does support the need for caution in interpreting the absolute value of the estimated effect sizes.

The available data for these other health endpoints, taken mostly from cross-sectional studies, are more limited and firm conclusions concerning causation cannot be made at this time.

Research Needs

Resolving residual confounding through observational studies

It may be somewhat easier to locate or configure populations in the <10 µg/dL range in which socioeconomic factors are not associated with exposure as compared to studies in a higher range in which more advantaged persons may be rare above 20 or 30 µg/dL. Configuring a cohort similar to the one in Boston or assembling one from the pieces of others already studied could be helpful in isolating socioeconomic and lead effects from one another. Another formal statistical approach that could be applied to pooled data across multiple studies is the application of a hierarchical modeling approach as proposed by Schwartz et al. (2003, in press).

Controlled intervention trials

While experimental designs can establish causation with greater confidence than observational studies, intentionally exposing some children to higher BLLs in a randomized controlled design would be unethical. However, randomized trials in which interventions are tested for their ability to reduce BLLs <10 : g/dL or prevent their increase provide an opportunity to support or refute a causal relationship between BLLs <10 : g/dL and adverse health outcomes. Studies testing such interventions should measure covariates relevant to assessing health effects, allowing a test of the causal hypothesis should they be successful at sufficiently reducing BLLs.

Animal and in vitro studies to explore mechanisms and dose-response relations

While the overall evidence from animal or in vitro models supports the biologic plausibility of adverse effects of lead at BLLs <10 : g/dL, the WG is unaware of directly relevant animal or in vitro studies that demonstrate a steeper slope for adverse effects of lead exposure at lower BLLs than observed at higher levels. Demonstrating such a relationship in experimental studies and identifying possible mechanisms would increase confidence in a causal interpretation of the observed blood lead-response relationship in studies such as Canfield et al. (2003).
Figure 1. Expected variation in regression slopes given hypothetical “true” threshold blood lead - IQ relation (A).
Notes: Figures 2 and 3

Selected estimates of change in outcome (Full Scale IQ or McCarthy General Cognitive Index (GCI) derived from regression coefficients and listed in Table 2 and the corresponding mean BLLs of the study population are displayed in Figures 2 and 3. Figure 2 contains results from studies where the BLLs were measured at ages ≤2 years, and outcome measures were measured at ages ≥4 years. Figure 3 contains the results when both the BLLs and outcome measures were measured at ages ≥4 years. Both the crude (open dot) and adjusted (solid dot) coefficients are displayed in the figures when both are available. (The Kosovo and European Multicenter Study papers did not provide the crude coefficient). Although multiple models for a single study population may have been fit to results from differing ages within the defined age categories, only the regression coefficients for the highest blood lead age (per study population) are included in the figures. (The highest outcome measure age was used as a tiebreaker when necessary.) Also, when models for both a concurrent blood lead measure and a lifetime average blood lead measure existed for the highest blood lead age (Port Pirie and Rochester), the concurrent results were included. For the study that provided multiple models for the same highest-age blood lead versus outcome measure (Lavrion, Greece), the results from the model that included the most covariates were included. Any studies not providing both a regression coefficient and blood lead mean were excluded. Three-letter abbreviations for each study population, defined in the legends below, were used on the plots.

Legend for Figure 2

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Study population</th>
<th>Reference number</th>
<th>Blood lead and outcome ages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bos</td>
<td>Boston</td>
<td>7</td>
<td>24 months / 10 years</td>
</tr>
<tr>
<td>Cin</td>
<td>Cincinnati</td>
<td>13</td>
<td>15-24 months / 6.5 years</td>
</tr>
<tr>
<td>Kos</td>
<td>Kosovo</td>
<td>37</td>
<td>24 months / 4 years</td>
</tr>
<tr>
<td>Por</td>
<td>Port Pirie</td>
<td>23</td>
<td>24 months / 4 years</td>
</tr>
<tr>
<td>Roc</td>
<td>Rochester</td>
<td>11</td>
<td>6-24 months / 5 years</td>
</tr>
</tbody>
</table>

Legend for Figure 3

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Study population</th>
<th>Reference number</th>
<th>Blood lead and outcome ages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bos</td>
<td>Boston</td>
<td>7</td>
<td>10 years / 10 years</td>
</tr>
<tr>
<td>Cin</td>
<td>Cincinnati</td>
<td>13</td>
<td>51-60 months / 6.5 years</td>
</tr>
<tr>
<td>Eur</td>
<td>European Multicenter Study</td>
<td>39</td>
<td>6-11 years / 6-11 years</td>
</tr>
<tr>
<td>Kar</td>
<td>Karachi</td>
<td>28</td>
<td>6-8 years / 6-8 years</td>
</tr>
<tr>
<td>Kos</td>
<td>Kosovo</td>
<td>37</td>
<td>48 months / 4 years</td>
</tr>
<tr>
<td>Lav</td>
<td>Lavrion, Greece</td>
<td>20</td>
<td>primary school / primary school</td>
</tr>
<tr>
<td>Por</td>
<td>Port Pirie</td>
<td>35</td>
<td>11-13 years / 11-13 years</td>
</tr>
<tr>
<td>Roc</td>
<td>Rochester</td>
<td>11</td>
<td>5 years / 5 years</td>
</tr>
</tbody>
</table>
Figure 2. Cognitive Function Regression Coefficients for Blood Lead Age ≤ 2 years and Outcome Age ≥ 4 years.
Figure 3. Cognitive Function Regression Coefficients for Blood Lead Age ≥ 4 years and Outcome Age ≥ 4 years.
A Review of Evidence of Health Effects of Blood Lead Levels <10 μg/dL in Children

Source: Tong et al. 1996.

Figure 4. Age trend in blood lead levels (BLLs).
A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

Figure 5. Hypothetical observed association between blood lead and IQ.

Figure 6. Hypothetical “true” association between blood lead and IQ.
Figure 7. Hypothetical slopes of the relationship between blood lead and IQ associated with residual confounding (see Overall Conclusions).
Table 1. Lowest blood lead level (BLL) considered elevated by CDC and the US Public Health Service

<table>
<thead>
<tr>
<th>Year and Reference</th>
<th>BLL (µg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1971 (Surgeon General)</td>
<td>40</td>
</tr>
<tr>
<td>1975 (CDC)</td>
<td>30</td>
</tr>
<tr>
<td>1978 (CDC)</td>
<td>30</td>
</tr>
<tr>
<td>1985 (CDC)</td>
<td>25</td>
</tr>
<tr>
<td>1991 (CDC)</td>
<td>10</td>
</tr>
</tbody>
</table>
Table 2.
Table 3.
Table 4.
### Table 5. Studies of health endpoints other than IQ or GCI in relation to BLLs <10 µg/dL.

<table>
<thead>
<tr>
<th>Study population (ref., type, n)</th>
<th>Health outcome</th>
<th>Age at measurement</th>
<th>BLL</th>
<th>Outcome</th>
<th>BLL distribution</th>
<th>Covariates</th>
<th>Results on BLL-outcome association &lt;10 µg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHANES III (22, X, 4853)</td>
<td>Cognitive function and academic achievement</td>
<td>6-16 years</td>
<td>Geometric mean (GM)=1.9 µg/dL, 98% &lt;10 µg/dL</td>
<td>Sex, race/ethnicity, poverty, region, parent/caregiver education and marital status, serum ferritin, serum cotinine.</td>
<td>Significant inverse relationships between BLL and WRAT arithmetic, WRAT reading, WISC R block design, WISC-R digit span. For all but block design, regression slopes became more negative with restriction of analyses to children with BLL &lt;10, &lt; 7.5, &lt; 5.0, and &lt; 2.5 µg/dL.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leipzig, Gardelegen, Duisberg, Germany (36, X, 384)</td>
<td>Attention, sensorimotor function, and cognitive function</td>
<td>5-7 years</td>
<td>4.25 µg/dL (GM), 95% &lt;9 µg/dL</td>
<td>Study area, visual acuity and contrast sensitivity, parental education, sex, breastfeeding, height, nationality.</td>
<td>For WISC vocabulary and block design: Study area, visual acuity and contrast sensitivity, age, parental education, sex, breastfeeding, height, nationality. For NES2 pattern comparison, pattern memory, tapping, simple reaction time, and continuous performance test: study area, visual acuity and contrast sensitivity, age, parental education, sex, birthweight, smoking in pregnancy, number of siblings, height, computer familiarity. Significant negative association between WISC vocabulary and CPT results. Associations strongest in Gardelegen, community with lowest mean BLL.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leipzig, Gardelegen, Duisberg, Germany (40, X, 367)</td>
<td>Neurobehavioral and neurophysiologic function</td>
<td>6 years</td>
<td>Median 5 µg/dL, 95% &lt;10 µg/dL</td>
<td>For NES2 tapping, benton (pattern memory), reaction time, pattern comparison: age, sex, parental education, study area. For Visual Evoked Potentials: age, gender, study area. Significant negative association of log transformed blood lead with tapping speed and with pattern comparison. No significant association of log-transformed BLL with visual evoked potential peak latencies.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New York (24, X, 68)</td>
<td>Mental development</td>
<td>12-36 months</td>
<td>Mean= 10.3 µg/dL</td>
<td>Receives public assistance, maternal education, HOME - Stim Q, child race, maternal IQ, anemia or low MCV, birth order, sex, age</td>
<td>Significantly lower Bayley MDI for children ≥10 µg/dL vs &lt;10; scatterplot of adjusted MDI vs. BLL suggests relation linear relation continues at BLL &lt;10.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

<table>
<thead>
<tr>
<th>Study population (ref., type, n)</th>
<th>Health outcome</th>
<th>Age at measurement</th>
<th>BLL</th>
<th>Outcome</th>
<th>BLL distribution</th>
<th>Covariates</th>
<th>Results on BLL-outcome association &lt;10 µg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leipzig, Gardelegen, Duisberg, Germany (1, X, 746)</td>
<td>NES1 – Tapping Test and pattern recognition</td>
<td>5 and 6 years</td>
<td>5 and 6 years</td>
<td>Median = 5 µg/dL and 95th percentile of overall frequency distribution for PbB was &lt;10 µg/dL</td>
<td>Maternal education, child’s sex, child’s age</td>
<td>Authors report that after adjustment for confounders a significant deficit for tapping and pattern comparison in relation to BLL (p&lt;0.05) was found, but no regression coefficient or dose-response analyses are presented.</td>
<td></td>
</tr>
<tr>
<td>Leipzig, Gardelegen, Duisberg, Germany (2, X, 384)</td>
<td>Visual function</td>
<td>5-7 years</td>
<td>5-7 years</td>
<td>4.25 µg/dL (GM), 95 % &lt;9 µg/dL</td>
<td>Child’s age, assessment site, birth weight, child’s medical history, head circumference, child weight, quality of fixation</td>
<td>Visual evoked potential interpeak latencies were significantly prolonged in relation to BLL for one of three visual stimuli tested and non-significantly prolonged for a second stimulus. No significant association between BLL and contrast sensitivity was seen.</td>
<td></td>
</tr>
<tr>
<td>[3] X - unstated (3, X, 400)</td>
<td>Neurotransmitter and neuroendocrine levels</td>
<td>8.5 - 12.3 years</td>
<td>8.5 - 12.3 years</td>
<td>Mean = 3.95</td>
<td>Ethnic group, iron status, dietary intake, medical history, sociodemographic factors, and household characteristics</td>
<td>No significant correlation overall between BLL and serum prolactin (Pro-S) or urinary homovanillic acid (HVA-U). Analysis performed on only those children BLL &gt;5 µg/dL showed a weak but statistically direct relation to BLL.</td>
<td></td>
</tr>
<tr>
<td>NHANES III (5, X, 4391)</td>
<td>Stature and head circumference</td>
<td>1-7 years</td>
<td>1-7 years</td>
<td></td>
<td>Significant inverse association of BLL to stature and head circumference (estimated decrease of 1.57 cm in stature and 0.52 cm in head circumference for each 10 µg/dL increase in BLL).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico City (30, L, 119-199)</td>
<td>Head circumference</td>
<td>every 6 months from 6-48 months</td>
<td>every 6 months from 6-48 months</td>
<td>Median postnatal varied from 7-10 µg/dL</td>
<td>Birth problems, child’s race, maternal head circumference, head circumference at birth</td>
<td>Natural log of blood lead at 12, 18, and 24 months significantly related to head circumference at 36 months; Natural log of blood lead at 12 months significantly related to head circumference at 42 months. Most other partial correlations between postnatal blood were negative. Plot of covariate adjusted head circumference at 36 months vs. natural log of blood lead at 12 months shows inverse relation that appears to continue below 10 µg/dL.</td>
<td></td>
</tr>
<tr>
<td>Lavrion, Elefsina, Loutraki Greece (21, X, 522)</td>
<td>Somatic growth, including head circumference, height, and chest circumference</td>
<td>6-9 years</td>
<td>6-9 years</td>
<td>Mean = 12.3 µg/dL, Median = 9.8 µg/dL</td>
<td>Paternal education, paternal occupation, child’s sex, child’s age, iron status, assessment site, father’s height, mother’s height</td>
<td>Significant negative association of BLL and head circumference and height with scatterplot suggesting relation continues below 10 µg/dL. No significant association with chest circumference.</td>
<td></td>
</tr>
</tbody>
</table>
## A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

<table>
<thead>
<tr>
<th>Study population</th>
<th>Age at measurement</th>
<th>Health outcome</th>
<th>BLL</th>
<th>Outcome</th>
<th>BLL distribution</th>
<th>Covariates</th>
<th>Results on BLL-outcome association &lt;10 µg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHANES III</td>
<td></td>
<td></td>
<td>8-18 years</td>
<td>8-18 years</td>
<td>Geometric means: Non-Hispanic whites: GM= 1.4; African Americans: GM= 2.1; Mexican Americans: GM= 1.7. BLLs greater than 5 µg/dL: 2.7%, 11.6% and 12.8%, respectively</td>
<td>Family income, ever smoked 100 cigarettes, child's age, iron status, child's medical history, height, BMI, age squared</td>
<td>Blood lead levels of 3 µg/dL (compared with 1 µg/dL) were associated with significant delays in breast and pubic hair development in African American and Mexican girls. The trend was similar, but not significant, for non-Hispanic white girls. Age at menarche was also delayed in relation to higher BLLs, but the association was only significant for African-American girls.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8-16 years</td>
<td>8-16 years</td>
<td>98.5% &lt;10; 54.3% 0-2.0</td>
<td>Poverty income ratio, family size, metro residence, child's age, child's race, BMI</td>
<td>Compared with BLLs 2.0 µg/dL and below, BLLs of 2.1-4.9 were associated with significantly lower odds of attaining tanner 2 stage pubic hair (OR=0.48, 95% CI 0.25-0.92) and menarche (OR=0.42, 95% CI 0.18-0.97); no significant association with breast development was noted.</td>
</tr>
</tbody>
</table>

(African American only)
### A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

<table>
<thead>
<tr>
<th>Study population (ref., type, n)</th>
<th>Health outcome</th>
<th>Age at measurement</th>
<th>BLL</th>
<th>Outcome</th>
<th>BLL distribution</th>
<th>Covariates</th>
<th>Results on BLL-outcome association &lt;10 µg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NHANES III (25, X, 24901)</td>
<td>Dental caries</td>
<td>2+ years</td>
<td>2+ years</td>
<td>Age 2-5 years: GM = 2.9; Age 6-11 years: GM = 2.1; Age 12+ years: GM = 2.5; 74-88% of participants with BLL &lt; 5 µg/dL in each age group</td>
<td>Poverty income ratio, maternal education, exposure to cigarette smoke, child's sex, child's age, child's race, assessment site, child's medical history, days since last dental visit, usual frequency of dental visits</td>
<td>Comparing children 5-17 years of age in middle tertile of BLL (range of BLLs: 1.7-4.1) to those in lowest tertile, odds ratio for dental caries was 1.36 (1.01-1.83)</td>
<td></td>
</tr>
<tr>
<td>Boston &amp; Cambridge, MA and Farmington, ME (18, X, 543)</td>
<td>Dental caries</td>
<td>6-10 years</td>
<td>6-10 years</td>
<td>Means: Cambridge/Boston 2.9 µg/dL; Farmington 1.7 µg/dL</td>
<td>Age, sex, family income, education of female guardian, ethnicity, maternal smoking, tooth brushing frequency, tooth brush bristle hardness, gum chewing</td>
<td>In Cambridge/ Boston number of carious surfaces increased significantly with log BLL in linear regression and in graph comparing children with BLL of 1, 2, and 3 µg/dL. In Farmington, non-significant decrease in carious surfaces with increasing BLL</td>
<td></td>
</tr>
<tr>
<td>Kosovo (17, L, 281)</td>
<td>Blood pressure</td>
<td>66 months</td>
<td>66 months</td>
<td>K. Mitrovica: mean=37.3 mcg/dL (sd=12.0); Pristina: mean=8.7 mcg/dL (sd=2.8)</td>
<td>For systolic blood pressure: birth order, child's sex, child's race, height, BMI; For diastolic blood pressure: birth order, child's race</td>
<td>Figures showing adjusted mean systolic and diastolic blood pressure for 10 groups with approximately equal numbers in each ordered by blood lead shows no consistent trend among the 4 across a range of BLL approximately 5-10 µg/dL.</td>
<td></td>
</tr>
<tr>
<td>Belgium (43, X, 143)</td>
<td>Heme synthesis biomarkers</td>
<td>10-13 years</td>
<td>10-13 years</td>
<td>Means: Boys: &lt; 1 km: 28.7 µg/dL (SD=8); 2.5 km: 15.6 (2.9); urban: 10.6 (2.0); rural: 9.2 (2.3) Girls: &lt; 1 km: 20.7 (7.6); 2.5 km: 9.8 (3.8); urban: 9 (2.0); rural: 8.7 (1.7)</td>
<td>Not specified</td>
<td>Dose-effect relationships are plotted for FEP, ALAD, and ALAU. No threshold evident for ALAD inhibition. Authors state if it exists it must be below 8-10 µg/dL. A BLL 5 threshold for increasing FEP evident at 15-20 µg/dL.</td>
<td></td>
</tr>
<tr>
<td>Boston (27, L, 249 originally recruited; 201 at 2 years)</td>
<td>Heme synthesis biomarkers</td>
<td>6-24 months</td>
<td>6-24 months</td>
<td>Mean 7 µg/dL</td>
<td>Not specified</td>
<td>No relationship between incidence of elevated erythrocyte protoporphyrin levels and BLLs below 15 µg/dL.</td>
<td></td>
</tr>
</tbody>
</table>
# A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children

<table>
<thead>
<tr>
<th>Study population (ref., type, n)</th>
<th>Health outcome</th>
<th>Age at measurement</th>
<th>BLL</th>
<th>Outcome</th>
<th>BLL distribution</th>
<th>Covariates</th>
<th>Results on BLL-outcome association &lt;10 µg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cincinnati (19, L, 165)</td>
<td>Heme synthesis biomarkers</td>
<td>6-30 months</td>
<td>6-30 months</td>
<td>Not presented</td>
<td>None presented, crude results only</td>
<td>Significant positive association reported for FEP and ZPP and ln transformed BLL at all ages. Threshold for relationship at BLL between 15 and 20 µg/dL.</td>
<td></td>
</tr>
<tr>
<td>Pribam, Czech Republic (9, X, 246)</td>
<td>Renal function</td>
<td>12-15 years</td>
<td>12-15 years</td>
<td>Mean ranged from 8.39 µg/dL in girls in the control area to 14.9 µg/dL in boys in polluted area 2</td>
<td>None presented, crude results only</td>
<td>Urinary RBP was found to be significantly associated with BLL in a stepwise regression. When urinary RBP excretion was examined by BLL tertiles, significantly lower U-RBP was seen in the group with BLL &lt;8.64 µg/dL compared with BLL 8.64-12.3.</td>
<td></td>
</tr>
</tbody>
</table>
Table 6
APPENDIX A:

LITERATURE REVIEW AND CLASSIFICATION UPDATE
Appendix A: Literature Review and Classification Update

The literature review began with the Agency for Toxic Substances and Disease Registry’s Toxicological Profile for Lead (ATSDR Tox Profile), published July 1999. The Health Effects chapter was thoroughly read and all articles relating to low blood lead levels in children were chosen, regardless of whether they demonstrated significant results. New literature searches were then performed by Battelle’s Technical Information Center. The year 1995 was chosen as the cutoff date for the new searches because it was felt that, before this time, research rarely focused on BLLs < 10 µg/dL, and that most relevant articles before 1995 were cited in the ATSDR Toxicological Profile. Searches were performed on a variety of databases using DIALOG and a set of keywords.

The following is an example of the DIALOG, including databases and keywords:

Set   Items   Description
S1    512735   NATAL? OR PRENATAL? OR PERINATAL? OR POSTNATAL?
S2    124432   INFANT? OR INFANCY
S3     2607491  CHILD? OR CHILDREN? ?
S4    253558   LEAD/TI,DE,ID
S5     184354   PB
S6     68959   RN=7439-92-1
S7    5798237   BLOOD
S8    14048   (S1:S3) AND (S4:S6) AND S7
S9    2153692   GROWTH/TI,DE,ID
S10    31450   STATURE
S11    634981   NUTRITION
S12    169948   HEARING
S13    200409   (RENAL OR KIDNEY)(3N)FUNCTION?
S14    669012   BLOOD()PRESSURE
S15     13     HEMESYNTHESIS
S16     61334   HEMATOPOIESIS
S17    20269   (VITAMIN()D)(3N)METABOLI?
S18     1441   S8 AND (S9:S17)
S19     438   S18 AND PY=1990:1996
S20     422   S19/ENG OR (S19 AND LA=ENGLISH)
S21     353   S20/HUMAN
S22     190   RD (unique items)
S23     190   Sort S22/ALL/PY,D
S24     19583   NEUROBEHAVIO?
S25     272980  NEUROLOGICAL?
S26     166224  NEUROLOGIC
S27     148942  NEUROTOXIC?
S28     15459   NEURODEVELOPMENT?
S29     7061   COGNITIVE()DEVELOPMENT
This literature search was first run for the years 1995-2002. In spring, 2003, the search was rerun for the years 2002-2003 to determine the relevance of recently published articles. Also at this time, the search was rerun for the years 1990-1996 for relevant articles that were not cited in the ATSDR Toxicological Profile. Titles and abstracts from each literature search were reviewed, and relevant articles were ordered for further review. Additional articles were identified while reviewing the selected articles and were added to the list of references, as were several articles recommended by workgroup members.

The table below provides a summary of all the articles obtained from the various sources. This table shows when the search was performed, the years covered in the search, the number of articles found in the literature search, the number of articles ordered after the titles and abstracts had been reviewed, and the number of articles that were relevant for abstraction.

### Summary of Literature Review Results

<table>
<thead>
<tr>
<th>Date of Search</th>
<th>Years Covered</th>
<th>Number of Unique References Found</th>
<th>Number of reviewed for relevance</th>
<th>Number of Articles Abstracted into the Database</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/02</td>
<td>1995-2002</td>
<td>327</td>
<td>79</td>
<td>12</td>
</tr>
<tr>
<td>4/03</td>
<td>2002-2003</td>
<td>119</td>
<td>14</td>
<td>4a</td>
</tr>
<tr>
<td>5/03</td>
<td>1990-1996</td>
<td>605</td>
<td>25</td>
<td>4</td>
</tr>
<tr>
<td>ATSDR Tox Profile</td>
<td>Prior to 1996</td>
<td>-</td>
<td>107</td>
<td>24</td>
</tr>
<tr>
<td>Referralsb</td>
<td>various</td>
<td>10</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td><strong>Total:</strong></td>
<td><strong>235</strong></td>
<td><strong>50</strong></td>
<td><strong>42</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Relevant articles cited in Tables 2-5**  

a A 5th article, Stone et al. 2003, was obtained from this search and is not abstracted into the database but its relevance is discussed elsewhere in the report.

b Referrals include articles that were recommended by workgroup members, as well as those articles cited as references in studies identified in the ATSDR Tox Profile or literature searches.
APPENDIX B:

DISCUSSION OF CRITIQUE OF
NHANES III DATA BY STONE ET AL. (2003)
Appendix B: Discussion of Critique of NHANES III Data by Stone et al. (2003)

Stone et al. (2003) reanalyzed the data used by Lanphear et al. (2000). While the results they present are largely consistent with the findings of Lanphear et al. (2000), they provided a critique of the validity of the NHANES III data for evaluating lead-related impacts on neuropsychological development in children. Because their critique cuts across on neuropsychological measurements performed in the survey, the main points of their paper are summarized in this appendix, as follows.

- Stone et al. note that the weighted mean values for the four measures used by Lanphear et al. are below the predicted mean based on standardization data for these tests collected in the early 1970s for the WISC-R and early 1980s for the WRAT. Stone et al. argue that the mean values should be higher than predicted by the standardization means because of secular improvements in cognitive test scores. One possible reason cited for the discrepancy is that NHANES tests were not administered by a psychologist. It is unclear, however, if the population sample used in the standardization data was equally representative of the U.S. population at that time or if changes in the population composition since then would lead to an increase or decrease in overall mean test performance. More importantly, it is unclear how a bias in mean score, even if real, and the use of non-psychologists for testing could produce associations between BLLs and test scores, given that examiners could not have known the participants' BLLs. If non-psychologists produced less precise test results than psychologists would have, the expected impact on regression coefficients would be a bias toward the null.

- The age-adjusted scores used in NHANES are correlated with age, and they should not be. Stone et al. show that age is negatively correlated with arithmetic, block design, and digit span and positively correlated with reading. However, since BLLs decrease with age across the age range studied, the negative correlations would tend to produce a trend towards higher scores with increasing blood lead for those tests, the opposite of the findings of Stone et al.

- Imputation of missing covariate values was performed for a substantial proportion of observations in the analyses performed by Lanphear et al. While imputation could increase covariate mismeasurement and residual confounding, analyses presented by Stone et al. demonstrate essentially similar findings when analyses are restricted to observations with full rank data.

- Relevant covariates, including whether a child has repeated a grade, whether interviews were in Spanish, and several other factors, were not included in analyses. However, two problems are evident in alternative “two stage” analysis provided by Stone et al. First, it uses predicted rather than residual blood lead level as an independent variable in a model relating blood lead to test scores. This amounts to testing the relation to test scores of a linear combination of covariates, many included in the model with test score as the outcome. In addition at least one variable – having to repeat a grade – is included as a covariate, possibly result serious over control as discussed earlier. Lead associated cognitive and behavioral effects have, not surprisingly, been associated with an increased
risk of failure to complete high school. Thus, controlling for failure to complete a grade could amount to controlling for an effect of, rather than a confounder of the lead effect.

As a whole, the Stone et al. critique of the NHANES III data do not provide a convincing argument that the findings reported by Lanphear et al. (2000) result from problems with the sample or testing methods. However, the WG did consider the limitations of the Lanphear et al. study, including its cross-sectional design and limited data on potential confounders. This study was weighed in the overall context of other relevant studies, including the more persuasive cohort studies, which are largely consistent with the associations Lanphear et al. report.
REFERENCES
References

Note: Table R-1, which follows this alphabetical listing of references, identifies the numbered references that are used in Tables 2 through 6 (which also are included in the alphabetical listing).


A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children


Bellinger, D. C. Interpreting the literature on lead and child development: the neglected role of the 'experimental system'. Neurotoxicol Teratol. 1995;17(3):201-212.


A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children


A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children


Centers for Disease Control and Prevention. Preventing Lead Poisoning in Young Children. CDC. Atlanta, Georgia. 1991.


A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children


A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children


U.S. Department of Housing and Urban Development. Economic analysis of the final rule on lead-based paint: Requirements for notification, evaluation, and reduction of lead-based
A Review of Evidence of Health Effects of Blood Lead Levels <10 µg/dL in Children


### Table R-1. Numbered references used in Tables 2 through 6.

<table>
<thead>
<tr>
<th>Reference Number</th>
<th>First Author</th>
<th>Publication Date</th>
<th>Journal Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Altmann, L.</td>
<td>1997</td>
<td>Assessment of neurophysiologic and neurobehavioral effects of environmental pollutants in 5- and 6-year-old children</td>
</tr>
<tr>
<td>2</td>
<td>Altmann, L.</td>
<td>1998</td>
<td>Visual functions in 6-year old children in relation to lead and mercury levels</td>
</tr>
<tr>
<td>3</td>
<td>Alvarez Leite, E. M.</td>
<td>2002</td>
<td>Urinary homovanillic acid and serum prolactin levels in children with low environmental exposure to lead</td>
</tr>
<tr>
<td>4</td>
<td>Baghurst, P. A.</td>
<td>1992</td>
<td>Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study</td>
</tr>
<tr>
<td>6</td>
<td>Bellinger, D. C.</td>
<td>1991</td>
<td>Low-level lead exposure and children's cognitive function in the preschool years</td>
</tr>
<tr>
<td>7</td>
<td>Bellinger, D. C.</td>
<td>1992</td>
<td>Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study</td>
</tr>
<tr>
<td>8</td>
<td>Bergomi, M.</td>
<td>1989</td>
<td>Relationship between lead exposure indicators and neuropsychological performance in children</td>
</tr>
<tr>
<td>9</td>
<td>Bernard, A.</td>
<td>1995</td>
<td>Renal effects in children living in the vicinity of a lead smelter</td>
</tr>
<tr>
<td>10</td>
<td>Calderon, J.</td>
<td>2001</td>
<td>Exposure to arsenic and lead and neuropsychological development in Mexican children</td>
</tr>
<tr>
<td>11</td>
<td>Canfield, R. L.</td>
<td>2003</td>
<td>Intellectual Impairment in Children with Blood Lead Concentrations below 10 ug per deciliter</td>
</tr>
<tr>
<td>12</td>
<td>Cooney, G. H.</td>
<td>1989</td>
<td>Low-level exposures to lead: the Sydney lead study</td>
</tr>
<tr>
<td>13</td>
<td>Dietrich, K. N.</td>
<td>1993</td>
<td>The developmental consequences of low to moderate prenatal and postnatal lead exposure: intellectual attainment in the Cincinnati Lead Study Cohort following school entry</td>
</tr>
<tr>
<td>14</td>
<td>Ernhart, C. B.</td>
<td>1987</td>
<td>Low level lead exposure in the prenatal and early preschool periods: early preschool development</td>
</tr>
<tr>
<td>15</td>
<td>Ernhart, C. B.</td>
<td>1988</td>
<td>Low level lead exposure and intelligence in the preschool years</td>
</tr>
<tr>
<td>16</td>
<td>Ernhart, C. B.</td>
<td>1989</td>
<td>Low level lead exposure in the prenatal and early preschool periods: intelligence prior to school entry</td>
</tr>
<tr>
<td>17</td>
<td>Factor-Litvak, P.</td>
<td>1996</td>
<td>Blood lead and blood pressure in young children</td>
</tr>
<tr>
<td>18</td>
<td>Gemmel, A</td>
<td>2002</td>
<td>Blood lead level and dental caries in school-age children</td>
</tr>
<tr>
<td>19</td>
<td>Hammond, P. B.</td>
<td>1985</td>
<td>Dose-effect and dose-response relationships of blood lead to erythrocytic protoporphyrin in young children</td>
</tr>
<tr>
<td>20</td>
<td>Hatzakis, A.</td>
<td>1987</td>
<td>Psychometric intelligence and attentional performance deficits in lead-exposed children</td>
</tr>
<tr>
<td>21</td>
<td>Kafourou, A.</td>
<td>1997</td>
<td>Effects of lead on the somatic growth of children</td>
</tr>
<tr>
<td>22</td>
<td>Lanphear, B. P.</td>
<td>2000</td>
<td>Cognitive deficits associated with blood lead concentrations</td>
</tr>
<tr>
<td>Reference Number</td>
<td>First Author</td>
<td>Publication Date</td>
<td>Journal Title</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------</td>
<td>------------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>23</td>
<td>McMichael, A. J.</td>
<td>1988</td>
<td>Port Pirie Cohort Study: environmental exposure to lead and children’s abilities at the age of four years</td>
</tr>
<tr>
<td>24</td>
<td>Mendelsohn, A. L.</td>
<td>1999</td>
<td>Low-level lead exposure and cognitive development in early childhood</td>
</tr>
<tr>
<td>25</td>
<td>Moss, M. E.</td>
<td>1999</td>
<td>Association of dental caries and blood lead levels</td>
</tr>
<tr>
<td>26</td>
<td>Munoz, H.</td>
<td>1993</td>
<td>Blood Lead Level and Neurobehavioral Development among Children Living in Mexico City</td>
</tr>
<tr>
<td>27</td>
<td>Rabinowitz, M. B.</td>
<td>1986</td>
<td>Occurrence of elevated protoporphyrin levels in relation to lead burden in infants</td>
</tr>
<tr>
<td>28</td>
<td>Rahman, A.</td>
<td>2002</td>
<td>Lead-associated deficits in stature, mental ability and behaviour in children in Karachi</td>
</tr>
<tr>
<td>29</td>
<td>Roels, H. A.</td>
<td>1987</td>
<td>Evaluation of dose-effect and dose-response relationships for lead exposure in different Belgian population groups (fetus, child, adult men and women)</td>
</tr>
<tr>
<td>30</td>
<td>Rothenberg, S. J.</td>
<td>1999</td>
<td>Pre- and postnatal lead effect on head circumference: a case for critical periods</td>
</tr>
<tr>
<td>31</td>
<td>Schnaas, L.</td>
<td>2000</td>
<td>Temporal pattern in the effect of postnatal blood lead level on intellectual development of young children</td>
</tr>
<tr>
<td>32</td>
<td>Selevan, S. G.</td>
<td>2003</td>
<td>Blood lead concentration and delayed puberty in girls</td>
</tr>
<tr>
<td>33</td>
<td>Silva, P. A.</td>
<td>1988</td>
<td>Blood lead, intelligence, reading attainment, and behavior in eleven year old children in Dunedin, New Zealand</td>
</tr>
<tr>
<td>34</td>
<td>Stiles, K. M.</td>
<td>1993</td>
<td>Neuropsychological correlates of low-level lead exposure in school-age children: A prospective study</td>
</tr>
<tr>
<td>35</td>
<td>Tong, S. L.</td>
<td>1996</td>
<td>Lifetime exposure to environmental lead and children's intelligence at 11-13 years: the Port Pirie cohort study</td>
</tr>
<tr>
<td>36</td>
<td>Walkowiak, J.</td>
<td>1998</td>
<td>Cognitive and sensorimotor functions in 6-year-old children in relation to lead and mercury levels: adjustment for intelligence and contrast sensitivity in computerized testing</td>
</tr>
<tr>
<td>37</td>
<td>Wasserman, G. A.</td>
<td>1994</td>
<td>Consequences of lead exposure and iron supplementation on childhood development at age 4 years</td>
</tr>
<tr>
<td>38</td>
<td>Wasserman, G. A.</td>
<td>1997</td>
<td>Lead exposure and intelligence in 7-year-old children: the Yugoslavia Prospective Study</td>
</tr>
<tr>
<td>39</td>
<td>Winneke, G.</td>
<td>1990</td>
<td>Results from the European Multicenter Study on lead neurotoxicity in children: implications for risk assessment</td>
</tr>
<tr>
<td>40</td>
<td>Winneke, G.</td>
<td>1994</td>
<td>Neurobehavioral and neurophysiological observations in six year old children with low lead levels in East and West Germany</td>
</tr>
<tr>
<td>41</td>
<td>Wolf, A. W.</td>
<td>1994</td>
<td>No Evidence of Developmental III Effects of Low-Level Lead Exposure in a Developing Country</td>
</tr>
</tbody>
</table>

R-14 October 7, 2004